Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Jin Seok Ahn 43 Articles
Lung and Thoracic cancer
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn
Cancer Res Treat. 2024;56(4):1084-1095.   Published online April 30, 2024
DOI: https://doi.org/10.4143/crt.2024.084
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).
Materials and Methods
In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39+PD-1+CD8+ T cells using fold changes in the percentage of proliferating Ki-67+ cells from days 1 to 7 of cycle 1 (Ki-67D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39+PD-1+CD8+ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.
  • 1,564 View
  • 111 Download
Close layer
First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data
Youngkyung Jeon, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2024;56(1):61-69.   Published online July 14, 2023
DOI: https://doi.org/10.4143/crt.2023.461
AbstractAbstract PDFPubReaderePub
Purpose
Alectinib and brigatinib are second-generation anaplastic lymphoma receptor tyrosine kinases (ALKs) that are widely used as first-line therapy for treating ALK-positive advanced non–small cell lung cancer (NSCLC). Given the lack of a head-to-head comparison of these drugs as first-line therapies, this retrospective observational study aimed to compare the real-world efficacy and safety of alectinib and brigatinib.
Materials and Methods
Patients who received alectinib or brigatinib as the first-line treatment for ALK-positive advanced NSCLC were evaluated for clinical outcomes of objective response rate (ORR), intracranial ORR, time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety profiles.
Results
Of 208 patients who received either alectinib or brigatinib as a first-line treatment, 176 received alectinib and 32 received brigatinib. At the data cutoff point, the median follow-up duration was 16.5 months (95% confidence interval [CI], 14.7 to 18.3) in the brigatinib group and 27.5 months (95% CI, 24.6 to 30.4) in the alectinib group. The ORR was 92.5% with alectinib and 93.8% for brigatinib. The intracranial ORR rates were 92.7% (38/41) and 100% (10/10), respectively. The rate of PFS at 12 months was comparable between the alectinib group and the brigatinib groups (84.4% vs. 84.1%, p=0.64), and the median TTNT, PFS, and OS were not reached in either group. Treatment-related adverse events were usually mild, and treatment discontinuation due to adverse events was rare (alectinib 4.5% vs. brigatinib 6.25%).
Conclusion
Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world.

Citations

Citations to this article as recorded by  
  • Bridging the Gap between Trial Adverse Events and Real-World Data
    Sang Hyuk Kim, Hyun Lee, Dong Won Park
    Cancer Research and Treatment.2024; 56(3): 972.     CrossRef
  • Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
    Jeong Eun Lee, Jin Hyun Nam, Sun Hong Kwon, Bo Kyung Kim, Seung Min Ha
    Cancer Medicine.2024;[Epub]     CrossRef
  • 4,633 View
  • 563 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
Youngkyung Jeon, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Se-Hoon Lee
Cancer Res Treat. 2023;55(4):1144-1151.   Published online May 22, 2023
DOI: https://doi.org/10.4143/crt.2023.403
AbstractAbstract PDFPubReaderePub
Purpose
Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded access program (EAP) use of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement.
Materials and Methods
Patients who received pralsetinib as part of the EAP at Samsung Medical Center were evaluated through a retrospective chart review. The primary endpoint was overall response rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 guidelines. Secondary endpoints were duration of response, progression-free survival (PFS), overall survival (OS), and safety profiles.
Results
Between April 2020 and September 2021, 23 of 27 patients were enrolled in the EAP study. Two patients who were not analyzed due to brain metastasis and two patients whose expected survival was within 1 month were excluded from the analysis. After a median follow-up period of 15.6 months (95% confidence interval [CI], 10.0 to 21.2), ORR was 56.5%, the median PFS was 12.1 months (95% CI, 3.3 to 20.9), and the 12-month OS rate was 69.6%. The most frequent treatment-related adverse events (TRAEs) were edema (43.5%) and pneumonitis (39.1%). A total of 8.7% of patients experienced extra-pulmonary tuberculosis. TRAEs with a common grade of three or worse were neutropenia (43.5%) and anemia (34.8%). Dose reduction was required in nine patients (39.1%).
Conclusion
Pralsetinib presents a clinical benefit when used in patients with RET-rearranged NSCLC, consistent with a pivotal study.

Citations

Citations to this article as recorded by  
  • Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib
    Giuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, Laura Bonanno, Annamaria Catino, Giulio Metro, Iacopo Petrini, Marco Russano, Antonio Passaro
    Critical Reviews in Oncology/Hematology.2024; 194: 104243.     CrossRef
  • RET Fusion Testing in Patients With NSCLC: The RETING Study
    Esther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, Rebeca Martinez, Marta Alonso, Daniel Curto, Beatriz Jimenez, Alejandra Caminoa, Amparo Benito, Pilar Garrido, Sergi Clave, Edurne Arriola, Isabel Esteban-Rodriguez, Javier De Castro, Irene San
    JTO Clinical and Research Reports.2024; 5(4): 100653.     CrossRef
  • Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study
    Dehua Liao, Minghui Long, Jiwen Zhang, Xingyu Wei, Fei Li, Ting Yan, Desong Yang
    Lung Cancer.2024; 196: 107936.     CrossRef
  • 3,003 View
  • 207 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2023;55(2):498-505.   Published online October 4, 2022
DOI: https://doi.org/10.4143/crt.2022.388
AbstractAbstract PDFPubReaderePub
Purpose
The impact of epidermal growth factor receptor (EGFR) mutation in locally advanced non–small cell lung cancer (NSCLC) remains controversial. This study was conducted to investigate the clinical outcomes and recurrence patterns after definitive chemoradiotherapy (CRT) in patients with unresectable stage III non-squamous-cell lung cancer according to EGFR mutation status.
Materials and Methods
We retrospectively reviewed 604 patients with pathologically confirmed stage III NSCLC who were treated with definitive CRT and were examined for EGFR mutation at Samsung Medical Center, Korea, from January 2013 to December 2018. Among them, we identified 236 patients with stage III non-squamous-cell lung cancer who were treated with definitive CRT and were examined for EGFR mutation status. We analyzed the frequency of EGFR mutation, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and recurrence pattern.
Results
Among 236 patients, EGFR mutation was detected in 71 patients (30.1%) and the median follow-up duration was 41.7 months. There were no significant differences in PFS (9.9 vs. 10.9 months, p=0.236), and ORR to CRT (93.0% vs. 90.3%, p=0.623) according to EGFR mutation status. However, the EGFR mutant group showed significantly higher recurrence (88.7% vs. 75.2%, p=0.022), distant metastasis (76.1% vs. 61.2%, p=0.036) rates, especially brain (38.0% vs. 12.7%, p < 0.001), and better median OS (59.2 vs. 41.3 months, p=0.037) compared with patients without EGFR mutation.
Conclusion
Patients with EGFR mutation–positive unresectable stage III non-squamous lung cancer exhibited higher recurrence and distant metastasis rates, especially brain metastasis.

Citations

Citations to this article as recorded by  
  • Brain metastasis screening in the molecular age
    Joanna K Tabor, Amanda Onoichenco, Vinayak Narayan, A Gabriella Wernicke, Randy S D’Amico, Morana Vojnic
    Neuro-Oncology Advances.2023;[Epub]     CrossRef
  • 4,225 View
  • 215 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Breast cancer
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im
Cancer Res Treat. 2023;55(2):523-530.   Published online November 8, 2022
DOI: https://doi.org/10.4143/crt.2022.1360
AbstractAbstract PDFPubReaderePub
Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by  
  • Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
    Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
    Biochemical Pharmacology.2024; 222: 116117.     CrossRef
  • Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
    Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
    Surgery Open Science.2023; 16: 171.     CrossRef
  • 4,428 View
  • 164 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Lung and Thoracic cancer
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Hyun Ae Jung, Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat. 2023;55(2):479-487.   Published online December 27, 2022
DOI: https://doi.org/10.4143/crt.2022.1344
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Brain metastasis is common in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study showed that brain radiotherapy (RT) before first-generation (first-G) EGFR–tyrosine kinase inhibitor (TKI) therapy is associated with longer overall survival than TKI therapy alone. However, there is no data regarding the role of additional brain RT before afatinib therapy.
Materials and Methods
Between October 2014 and June 2019, EGFR-mutant NSCLC patients with brain metastases who started first-G EGFR-TKIs (gefitinib or erlotinib) or afatinib as first-line therapy were retrospectively analyzed. This study compared overall survival and intracranial progression-free survival (PFS) between patients who received EGFR-TKIs alone and EGFR-TKIs with brain RT and either a first-G EGFR-TKI or afatinib, respectively.
Results
The median follow-up duration was 29.6 months (range, 1.5 to 116.9 months). In the first-G EGFR-TKI group (n=155), 94 patients (60.6%) received the first-G EGFR-TKI alone and 61 patients (39.4%) received brain RT prior to their first-G EGFR-TKI. In the afatinib group (n=204), 126 patients (61.8%) received afatinib alone and 78 patients (38.2%) received brain RT prior to afatinib. There was no difference in overall survival rates between the groups with RT (35.6 months: 95% confidence interval [CI], 27.9 to 43.3) and without RT (31.4 months: 95% CI, 23.9 to 38.9) in the afatinib group (p=0.58), but there was a significant difference in overall survival in the first-G EGFR-TKI group in a manner favoring additional brain RT (41.1 months: 95% CI, 30.5 to 51.7 vs. 25.8 months: 95% CI, 20.1 to 31.5; p=0.02). Meanwhile, median intracranial PFS was not different between patients who received EGFR-TKI therapy alone vs. EGFR-TKI therapy with brain RT in both the first-G EGFR-TKI (p=0.39) and afatinib (p=0.24) groups.
Conclusion
Afatinib therapy alone showed comparable survival outcomes to those of afatinib with brain RT. The current study suggests that brain RT could be an optional, not mandatory, treatment modality when afatinib therapy is considered in patients with EGFR-mutant NSCLC.

Citations

Citations to this article as recorded by  
  • Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments
    Francesca Grassi, Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Michela Gabelloni, Alessandra Borgheresi, Ginevra Danti, Carmine Picone, Andrea Giovagnoni, Vittorio Miele, Nicoletta Gandolfo, Antonio Barile, Valerio Nardone, Roberta G
    Journal of Clinical Medicine.2023; 12(4): 1442.     CrossRef
  • Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
    H.A. Jung, S. Park, S.-H. Lee, J.S. Ahn, M.-J. Ahn, J.-M. Sun
    ESMO Open.2023; 8(6): 102068.     CrossRef
  • Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review
    Jiamin Xu, Zhongming Wang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 3,799 View
  • 150 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2023;55(1):103-111.   Published online June 20, 2022
DOI: https://doi.org/10.4143/crt.2022.264
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
Materials and Methods
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
Results
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
Conclusion
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.

Citations

Citations to this article as recorded by  
  • Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
    Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
    Cancer Research and Treatment.2024; 56(1): 104.     CrossRef
  • The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round
    Alberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, Giuseppe Mangiameli, Ezio Lanza, Manuel Profili, Fabrizio Bianchi, Emanuela Fina, Giuseppe Ferrante, Simone Ghislandi, Daniela Pistillo, Giovanna Finocchiaro, Gianluigi Condorelli, Rosalba Lembo,
    Cancers.2024; 16(2): 417.     CrossRef
  • Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
    Hyeon Hwa Kim, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, Jeong Eun Lee, Chan Kwon Park, Kye Young Lee, Sung Yong Lee, Seung Joon Kim, Jun Hyeok Lim, Chang-min Choi
    Cancers.2024; 16(3): 528.     CrossRef
  • Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation
    Theofanis Vavilis, Maria Louiza Petre, Giannis Vatsellas, Alexandra Ainatzoglou, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis N. Vamvakaris, Ioannis Gkiozos, Konstantinos N. Syrigos, Athanasios K. Anagnostopoulos
    Cancers.2024; 16(6): 1236.     CrossRef
  • Survival analysis and gender differences in hypertrophic cardiomyopathy proband patients referred for genetic testing
    Rebeca Lorca, María Salgado, Rut Álvarez-Velasco, Julián R. Reguro, Vanesa Alonso, Juan Gómez, Eliecer Coto, Elías Cuesta-Llavona, Eva Lopez-Negrete, Isaac Pascual, Pablo Avanzas, Maite Tome
    International Journal of Cardiology.2024; 408: 132117.     CrossRef
  • 18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
    Chae Hong Lim, Sang-Won Um, Hong Kwan Kim, Yong Soo Choi, Hong Ryul Pyo, Myung-Ju Ahn, Joon Young Choi
    Cancers.2024; 16(14): 2525.     CrossRef
  • Study Progress of Circulating miRNA for Predicting Metastasis in Non-Small Cell Lung Cancer
    靖靖 丛
    Advances in Clinical Medicine.2024; 14(07): 65.     CrossRef
  • Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression
    Jolanta Smok-Kalwat, Paulina Mertowska, Sebastian Mertowski, Stanisław Góźdź, Ewelina Grywalska
    Journal of Clinical Medicine.2024; 13(15): 4531.     CrossRef
  • Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer
    Cameron J. Oswalt, Morgan M. Nakatani, Jesse Troy, Steven Wolf, Susan C. Locke, Thomas W. LeBlanc
    Journal of Pain and Symptom Management.2024; 68(4): e325.     CrossRef
  • Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen–Autoantibody Immune Complexes against CYFRA 21-1 and p53
    Heyjin Kim, Jin Kyung Lee, Hye-Ryoun Kim, Young Jun Hong
    Cancers.2024; 16(15): 2661.     CrossRef
  • Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile
    Chinbayar Batochir, In Ae Kim, Eun Ji Jo, Eun-Bi Kim, Hee Joung Kim, Jae Young Hur, Do Won Kim, Hee Kyung Park, Kye Young Lee
    Cancers.2024; 16(15): 2765.     CrossRef
  • The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1
    Shuang Li, Junting Chen, Baosen Zhou
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • A Highly Sensitive Toluene Gas Sensor Based on Pd/PdO Decorated SnO2 Prepared by Electrospinning
    Chengyi Gong, Meng Chen, Fei Song, Peisi Yin, Xin Zhao, Xiaoyu You, Huaian Fu, Shanshan Yu, Xingyu Liu, Kai Zhang, Yongqi Yang, Zhipeng Tang, Xiangmin Du, Jiacong Xu, Qiang Jing, Bo Liu
    ACS Applied Electronic Materials.2024;[Epub]     CrossRef
  • miR-137: a potential therapeutic target for lung cancer
    Shuanshuan Liu, Yanyun Ruan, Xu Chen, Bao He, Qi Chen
    Frontiers in Cell and Developmental Biology.2024;[Epub]     CrossRef
  • Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis
    Junfang Zhang, Xuan Tang, Wenbo Zhang, Ying Xu, Heng Zhang, Yu Fan
    International Journal of Obesity.2024;[Epub]     CrossRef
  • Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
    Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
    European Journal of Medicinal Chemistry.2024; 280: 116952.     CrossRef
  • CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
    Suet Kee Loo, Gabriel Sica, Xian Wang, Tingting Li, Luping Chen, Autumn Gaither-Davis, Yufei Huang, Timothy F. Burns, Laura P. Stabile, Shou-Jiang Gao
    Cell & Bioscience.2024;[Epub]     CrossRef
  • Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection
    Silvia D’Ambrosi, Stavros Giannoukakos, Mafalda Antunes-Ferreira, Carlos Pedraz-Valdunciel, Jillian W. P. Bracht, Nicolas Potie, Ana Gimenez-Capitan, Michael Hackenberg, Alberto Fernandez Hilario, Miguel A. Molina-Vila, Rafael Rosell, Thomas Würdinger, Da
    International Journal of Molecular Sciences.2023; 24(5): 4881.     CrossRef
  • Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years
    Jee Seon Kim, Eun Ji Kim, Jong Geol Jang, Kyung Soo Hong, June Hong Ahn
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7275.     CrossRef
  • Prior treated tuberculosis and mortality risk in lung cancer
    Kuang-Ming Liao, Chung-Shu Lee, Yu-Cih Wu, Chin-Chung Shu, Chung-Han Ho
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • All-round counterattack to conquer lung cancer
    Seung Hun Jang
    Journal of the Korean Medical Association.2023; 66(3): 154.     CrossRef
  • Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction
    Kyung Soo Kim, Seok Whan Moon, Mi Hyung Moon, Kwan Yong Hyun, Seung Joon Kim, Young Koon Kim, Kwang Youl Kim, Dong Wook Jekarl, Eun-Jee Oh, Yonggoo Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • STEMI in women. Life expectancy recovery after primary percutaneous coronary intervention
    Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
    Revista Española de Cardiología (English Edition).2023; 76(12): 1003.     CrossRef
  • A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients
    Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu
    Healthcare.2023; 11(12): 1745.     CrossRef
  • IAMCEST en mujeres. Recuperación de la expectativa de vida tras la intervención coronaria percutánea
    Marcel Almendárez, Rut Álvarez-Velasco, Pablo Avanzas, Alberto Alperi, Luis Gutiérrez, David Ledesma, Javier Martínez, Daniel Hernández-Vaquero, Rebeca Lorca, Luis Arboine, Cesar Morís, Isaac Pascual
    Revista Española de Cardiología.2023; 76(12): 1003.     CrossRef
  • Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
    Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
    JMIR Medical Informatics.2023; 11: e47859.     CrossRef
  • Exosomes in lung cancer metastasis, diagnosis, and immunologically relevant advances
    Jianhua Zhao, Xiwen Li, Lele Liu, Zhen Zhu, Chunyan He
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • 8,520 View
  • 421 Download
  • 33 Web of Science
  • 27 Crossref
Close layer
Breast cancer
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1091-1098.   Published online January 10, 2022
DOI: https://doi.org/10.4143/crt.2021.901
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist.
Materials and Methods
We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020.
Results
Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%).
Conclusion
Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.

Citations

Citations to this article as recorded by  
  • De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
    Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang
    World Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
    Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
    The Breast.2024; 75: 103733.     CrossRef
  • Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
    Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sem
    Acta Oncologica.2023; 62(4): 381.     CrossRef
  • Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials
    Faizan Fazal, Muhammad Nauman Bashir, Maham Leeza Adil, Usama Tanveer, Mansoor Ahmed, Taha Zahid Chaudhry, Ali Ahmad Ijaz, Muhammad Haider
    Cureus.2023;[Epub]     CrossRef
  • Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study
    Yeon Jin Kim, Hye Jin Kim, Soo Yeon Chung, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jai Min Ryu
    Annals of Surgical Treatment and Research.2023; 105(1): 10.     CrossRef
  • Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
    Inês Soares de Pinho, Paulo Luz, Lucy Alves, Raquel Lopes-Brás, Vanessa Patel, Miguel Esperança-Martins, Lisa Gonçalves, Ritas Freitas, Diana Simão, Maria Roldán Galnares, Isabel Fernandes, Silvia Artacho Criado, Salvador Gamez Casado, Jose Baena Cañada,
    Clinical Drug Investigation.2023; 43(9): 691.     CrossRef
  • Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
    Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
    The Breast.2023; 72: 103594.     CrossRef
  • Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer
    Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, Min Hwan Kim, Jae Ho Jeong, Ji-Yeon Kim, Dae-Won Lee, Jin-Hee Ahn, Heejung Chae, Kyung-Hun Lee, Jee Hyun Kim, Keun Seok Lee, Joo Hyuk Sohn, Yoon-La Choi, Seock-Ah Im, Kyung Hae Jung, Yeon Hee Park
    JAMA Oncology.2022; 8(9): 1271.     CrossRef
  • 7,589 View
  • 576 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1130-1137.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.1103
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. We assessed the outcomes of THP as a first-line treatment for Korean HER2-positive MBC patients in the real-world setting.
Materials and Methods
Between August 2008 and October 2020, we identified 228 HER2-positive MBC patients who received THP as a first-line palliative chemotherapy. We analyzed survival outcomes, efficacy, and adverse events of THP retrospectively.
Results
After a median follow-up duration of 28.7 months, median overall survival and progression-free survival were 58.3 months (95% confidence interval [CI], 36.6 to 80.0) and 19.1 months (95% CI, 16.2 to 21.9), respectively. Better survival outcomes were observed in patient who received docetaxel for more than six cycles. Patients exposed to anti-HER2 directed therapies in a perioperative setting had poor survival outcomes. The overall response rate was 86.8% with a complete response (CR) rate of 17.7%. Among responders, 16.7% of patients sustained THP over 35 months and showed better survivals and higher CR rates. Adverse events were comparable to those reported in previous studies.
Conclusion
In a real-world context, clinical outcomes of Korean HER2-positive MBC patients treated with THP were similar to those of patients in the CLEOPATRA trial. Much longer follow-up results would be warranted.

Citations

Citations to this article as recorded by  
  • Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
    Kelvin KH. Bao, Jeffrey CH. Chan, Jocelyn G. Chan, Leone Sutanto, Ka Man Cheung, Harry HY. Yiu
    The Breast.2024; 73: 103612.     CrossRef
  • Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review
    Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, Liang Yin
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation
    Muhammad Javed Iqbal, Zeeshan Javed, Jesús Herrera-Bravo, Haleema Sadia, Faiza Anum, Shahid Raza, Arifa Tahir, Muhammad Naeem Shahwani, Javad Sharifi-Rad, Daniela Calina, William C. Cho
    Cancer Cell International.2022;[Epub]     CrossRef
  • 6,122 View
  • 298 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
General
Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors
Danbee Kang, Youngha Kim, Jihyun Lim, Junghee Yoon, Sooyeon Kim, Eunjee Kang, Heesu Nam, Sungkeun Shim, Mangyeong Lee, Haesook Bok, Sang-Won Lee, Soo-Yong Shin, Jin Seok Ahn, Dongryul Oh, Juhee Cho
Cancer Res Treat. 2022;54(1):10-19.   Published online April 9, 2021
DOI: https://doi.org/10.4143/crt.2020.1200
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of the study was to validate the Korean version of Patient-Reported Outcomes Measurement Information System 29 Profile v2.1 (K-PROMIS-29 V2.1) among cancer survivors.
Materials and Methods
Participants were recruited from outpatient clinics of the Comprehensive Cancer Center at the Samsung Medical Center in Seoul, South Korea, from September to October 2018. Participants completed a survey questionnaire that included the K-PROMIS-29 V2.1 and the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30). Principal component analysis and confirmatory factor analysis (CFA) and Pearson’s correlations were used to evaluate the reliability and validity of the K-PROMIS-29 V2.1.
Results
The mean age of the study participants was 54.4 years, the mean time since diagnosis was 1.2 (±2.4) years, and 349 (87.3%) completed the entire questionnaire. The Cronbach’s alpha coefficients of the seven domains in the K-PROMIS-29 V2.1 ranged from 0.81 to 0.96, indicating satisfactory internal consistency. In the CFA, the goodness-of-fit indices for the K-PROMIS-29 V2.1 were high (comparative fit index, 0.91 and standardized root-mean-squared residual, 0.06). High to moderate correlations were found between comparable subscales of the K-PROMIS-29 V2.1 and subscales of the EORTC QLQ-C30 (r=0.52-0.73).
Conclusion
The K-PROMIS-29 V2.1 is a reliable and valid measure for assessing the health-related quality of life domains in a cancer population, thus supporting their use in studies and oncology trials.

Citations

Citations to this article as recorded by  
  • Path analysis of illness uncertainty and psychosocial adaptation of patients with Marfan syndrome
    Sujin Kim, Yeonsoo Jang, JiYeon Choi, Kijun Song, Jae-kwan Song, Mona Choi
    European Journal of Cardiovascular Nursing.2024; 23(2): 197.     CrossRef
  • A single-armed proof-of-concept study of Lymfit: A personalized, virtual exercise intervention to improve health outcomes in lymphoma survivors in the pandemic
    Christopher Angelillo, Wing Lam Tock, Matthew Salaciak, Ryan E. R. Reid, Ross E. Andersen, Christine Maheu, Nathalie A. Johnson, Miquel Vall-llosera Camps
    PLOS ONE.2024; 19(1): e0275038.     CrossRef
  • Psychometric validation of the Functional Assessment of Cancer Therapy‐Endometrial among endometrial cancer patients
    Sooyeon Kim, Joseph J. Noh, Youngha Kim, Juhee Cho, Danbee Kang, Yoo‐Young Lee
    Cancer Medicine.2024;[Epub]     CrossRef
  • Hungarian PROMIS-29+2: psychometric properties and population reference values
    Balázs Jenei, Alex Bató, Ariel Z. Mitev, Valentin Brodszky, Fanni Rencz
    Quality of Life Research.2023; 32(8): 2179.     CrossRef
  • Preliminary evaluation of the Chinese version of the patient-reported outcomes measurement information system 29-item profile in patients with aortic dissection
    Wanbing Huang, Qiansheng Wu, Yufen Zhang, Chong Tian, Haishan Huang, Sufang Huang, Yanrong Zhou, Jing He, Hui Wang
    Health and Quality of Life Outcomes.2022;[Epub]     CrossRef
  • Psychometric validation of the Korean version of PROMIS 29 Profile V2.1 among patients with lower extremity problems
    Youngha Kim, Danbee Kang, Eunjee Kang, Jihyun Lim, Sooyeon Kim, Heesu Nam, Sungkeun Shim, Mangyeong Lee, Young-Wan Moon, Seung-Jae Lim, Ki-Sun Sung, Juhee Cho
    BMC Sports Science, Medicine and Rehabilitation.2021;[Epub]     CrossRef
  • 7,664 View
  • 246 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Lung and Thoracic cancer
Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2022;54(1):150-156.   Published online May 6, 2021
DOI: https://doi.org/10.4143/crt.2021.306
AbstractAbstract PDFPubReaderePub
Purpose
Metachronous brain-only oligorecurrence in patients with non–small cell lung cancer (NSCLC) is a rare event with favorable prognosis, but the clinical outcome has not been fully determined. We retrospectively analyzed clinical outcomes and prognostic factors in metachronous brain-only oligorecurrence in patients with NSCLC who underwent definitive treatment.
Materials and Methods
We reviewed 4,437 NSCLC patients without oncogenic driver mutations who underwent definitive treatment between 2008 and 2018. Among them, we identified 327 patients who developed 1 to 5 brain metastases with or without systemic metastasis. Of the 327 patients, 71 had metachronous brain-only oligorecurrence without extracranial progression and were treated with local therapy to the brain. Overall survival (OS), progression-free survival (PFS), and prognostic factors affecting OS were analyzed.
Results
The median OS was 38.9 months (95% confidence interval [CI], 21.8 to 56.1 months) in 71 patients. The 2-year OS rate was 67.8% and the 5-year OS rate was 33.1%. The median PFS was 25.5 months (95% CI, 12.2 to 14.4 months). The longest surviving patient had a survival period of 115 months. Through multivariate analysis, Eastern Cooperative Oncology Group ≥ 1 (hazard ratio, 5.33; p=0.005) was associated with poor survival. There was no significant difference in OS between patients with local therapy and those with local plus systemic therapy (18.5 months vs. 34.7 months, p=0.815).
Conclusion
Metachronous brain-only oligorecurrence NSCLC patients who underwent definitive treatment experienced long-term survival with local therapy, highlighting the unique patient population. The role of systemic chemotherapy in this patient population requires further investigation.

Citations

Citations to this article as recorded by  
  • Brain Metastasis of Non-small Cell Lung Cancer After Disease-Free Survival of 5 years: Case Series and Comprehensive Literature Review
    Takahiro Suzuki, Shoichi Deguchi, Keigo Matsushima, Shinya Katsumata, Hideaki Kojima, Maeda Koki, Hayato Konno, Mitsuhiro Isaka, Takuma Oishi, Yasuhisa Ohde, Takashi Sugino, Koichi Mitsuya, Nakamasa Hayashi
    World Neurosurgery.2024; 186: e353.     CrossRef
  • Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence
    Raphael Werner, Nina Steinmann, Herbert Decaluwe, Hiroshi Date, Dirk De Ruysscher, Isabelle Opitz
    European Respiratory Review.2024; 33(172): 230200.     CrossRef
  • 5,977 View
  • 153 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020
DOI: https://doi.org/10.4143/crt.2020.278
AbstractAbstract PDFPubReaderePub
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

Citations

Citations to this article as recorded by  
  • Research Advances of Small Molecule EGFR-TKIs in NSCLC
    亚南 胡
    Pharmacy Information.2024; 13(01): 1.     CrossRef
  • An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
    Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta, Ganesh Andhale
    Journal of Biomolecular Structure and Dynamics.2024; 42(3): 1564.     CrossRef
  • The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
    Yu Zhang, Chengmeng Wang, Jing Zhao, Meng Wang
    Thoracic Cancer.2024; 15(23): 1757.     CrossRef
  • Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
    Yue Fang, Qiankun Zhang, Weimin Wang, Juanjuan Tong, Xialin Li
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship
    Tanuja T. Yadav, Gulam Moin Shaikh, Maushmi S. Kumar, Meena Chintamaneni, Mayur YC
    Frontiers in Chemistry.2022;[Epub]     CrossRef
  • Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
    David E. Heppner, Florian Wittlinger, Tyler S. Beyett, Tatiana Shaurova, Daniel A. Urul, Brian Buckley, Calvin D. Pham, Ilse K. Schaeffner, Bo Yang, Blessing C. Ogboo, Earl W. May, Erik M. Schaefer, Michael J. Eck, Stefan A. Laufer, Pamela A. Hershberger
    ACS Medicinal Chemistry Letters.2022; 13(12): 1856.     CrossRef
  • Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong
    Pharmaceuticals.2021; 14(6): 589.     CrossRef
  • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
    BMB Reports.2021; 54(7): 386.     CrossRef
  • 7,696 View
  • 326 Download
  • 18 Web of Science
  • 8 Crossref
Close layer
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kim
Cancer Res Treat. 2020;52(3):907-916.   Published online March 18, 2020
DOI: https://doi.org/10.4143/crt.2019.713
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)–induced nausea and vomiting.
Materials and Methods
Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by gender, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6.
Results
A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], −7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, −2.3%; 95% CI, −13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, −7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups.
Conclusion
In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.

Citations

Citations to this article as recorded by  
  • Impact of body weight-based dosing of palonosetron and ondansetron on postoperative nausea and vomiting following laparoscopic sleeve gastrectomy: a randomized, double-blind study
    Büşra Burcu, Nadir Adnan Hacım, Ozan Caliskan, Serdar Demirgan, Talar Vartanoglu Aktokmakyan, Serhat Meric, Tomris Duymaz, Onder Karabay, Ali Solmaz
    Acta Chirurgica Belgica.2024; 124(1): 41.     CrossRef
  • 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents
    Jørn Herrstedt, L Celio, PJ Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
    J. Herrstedt, R. Clark-Snow, C.H. Ruhlmann, A. Molassiotis, I. Olver, B.L. Rapoport, M. Aapro, K. Dennis, P.J. Hesketh, R.M. Navari, L. Schwartzberg, M.L. Affronti, M.A. Garcia-Del-Barrio, A. Chan, L. Celio, R. Chow, M. Fleury, R.J. Gralla, R. Giusti, F.
    ESMO Open.2024; 9(2): 102195.     CrossRef
  • Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
    Baoxia Fang, Lijun Zhao, Shirong Yu, Fuchao Chen
    Dose-Response.2024;[Epub]     CrossRef
  • Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
    Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagnì, Valeria Altamura, Giovanni Scambia, Gennaro Daniele
    Cancer Treatment Reviews.2023; : 102512.     CrossRef
  • Effect of Acupuncture on Delayed Emesis for the Patients Who Received High-Emetogenic Chemotherapy with Standard Antiemetic Prophylaxis (KHMC-HO-01): An Open-Label, Randomized Study
    Chi Hoon Maeng, Seunghoon Lee, Jae Joon Han, Hong Jun Kim, Dongwoo Nam, Junhee Lee, Sun Kyung Baek, Maria Grazia Ferraro
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway
    Mei Qian, Yang Liu
    Acta Cirúrgica Brasileira.2022;[Epub]     CrossRef
  • Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis
    Hyo Jin Kim, EunJin Ahn, Geun Joo Choi, Hyun Kang
    Journal of Personalized Medicine.2022; 13(1): 82.     CrossRef
  • Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
    Timothy L. Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase, Ashraf S. Habib, Mark A. Demitrack, Michael J. Fossler, Eugene R. Viscusi
    Pain and Therapy.2021; 10(1): 401.     CrossRef
  • Forsythiae Fructus aqueous extract attenuates cisplatin-induced kaolin consumption (pica) by inhibiting NLRP3 inflammasome activation in rats
    Qi Meng, Pingping Bi, Guanglong Zhang, Yaqi Li, Siqi Chen, Ke Nie
    Bioscience, Biotechnology, and Biochemistry.2021; 85(9): 2054.     CrossRef
  • Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
    Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis
    Ajay Raghunath, Sahan D. Chandrasekara, Shane N. Anthony, Ben Markman
    Critical Reviews in Oncology/Hematology.2020; 152: 103012.     CrossRef
  • 9,421 View
  • 198 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Kangkook Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(1):292-300.   Published online July 26, 2019
DOI: https://doi.org/10.4143/crt.2019.186
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Human epidermal growth factor receptor 2 (HER2) alterations are found in approximately 1%-3% of non-small cell lung cancers (NSCLCs). We evaluated the clinical features and outcomes of NSCLC harboring HER2 alteration detected by next-generation sequencing (NGS) in Korea.
Materials and Methods
A total of 1,108 patients who were diagnosed with NSCLC between December 2015 and December 2017 were screened and analyzed by NGS. Medical records were reviewed retrospectively to analyze the clinical characteristics and outcomes from various treatments.
Results
HER2 alterations were identified in 36 NSCLC patients. Of the patients, 22 (61.1%) had an exon 20 in-frame insertion mutation, 15 (41.7%) had HER2 amplification, and one had both. The median patient age was 58 years, 55.6% were male, and 50.0% were never-smokers. Adenocarcinoma was predominant (88.9%). The most common metastatic site was bone (58.3%), and 66.7% of patients were stage IV at initial diagnosis. Six patients (16.7%) had a coexistent sensitizing epidermal growth factor receptor (EGFR) mutation, and two patients (5.6%) had anaplastic lymphoma kinase (ALK) rearrangement. With a median 14 months of follow-up, the median progression-free survival of first-line treatment was 6 months (95% confidence interval, 4.172 to 7.828), and median overall survival was not reached. The proportions of adenocarcinoma, never-smokers, and metastasis to the liver were higher in the exon 20 in-frame insertion mutation group, whereas coexistence of EGFR mutation was more frequently found in the HER2 amplification group.
Conclusion
HER2-altered NSCLC showed distinct clinical features. Moreover, different characteristics were identified between the HER2 in-frame insertion mutation group and the HER2 amplification group.

Citations

Citations to this article as recorded by  
  • Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
    Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han
    Modern Pathology.2024; 37(6): 100490.     CrossRef
  • The frequency of EGFR gene mutations in a cohort of Romanian patients with non-small cell lung cancer and their association with PD-L1 expression level and ALK rearrangements
    Ester-Andreea Cohn, Ortansa Csutak, Ecaterina Tataru
    Revista Romana de Medicina de Laborator.2024; 32(3): 237.     CrossRef
  • Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
    David J. H. Bian, Sara F. Cohen, Anna-Maria Lazaratos, Nathaniel Bouganim, Matthew Dankner
    Current Oncology.2024; 31(10): 6314.     CrossRef
  • ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
    Hui Li, Xiang Li, Shaowei Lan, Xuerong Zuo, Tianying Du, Ying Liu, Caixia Zhang, Jing Zhu, Ying Cheng
    Tumori Journal.2023; 109(3): 276.     CrossRef
  • Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
    Xiaoli Zhuo, Honglin Guo, Jun Ma, Jingjiang Lai, Lei Liu, Ke Yin, Jing Zhao, Jingliang Wang, Fengxian Jiang, Wei Xu, Xiaotian Yuan, Xiaoyan Lin, Guobin Fu
    Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2029.     CrossRef
  • Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
    Beung-Chul Ahn, Ye-Jeong Han, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
    Cancer Research and Treatment.2023; 55(2): 488.     CrossRef
  • Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
    Ola Abu Al Karsaneh, Arwa Al Anber, Mohammad ALQudah, Sahar Al-Mustafa, Hussien AlMa’aitah, Maher Sughayer
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients
    Maomei Ruan, Cheng Chang, Jianwen Sun, Liu Liu, Lihua Wang, Bei Lei, Hui Yan, He Zhang, Wenhui Xie, Yuetao Wang
    Journal of Cancer Research and Clinical Oncology.2023; 149(16): 14493.     CrossRef
  • Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
    Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lu
    Clinical Cancer Research.2022; 28(3): 461.     CrossRef
  • Consensus for HER2 alterations testing in non-small-cell lung cancer
    S. Ren, J. Wang, J. Ying, T. Mitsudomi, D.H. Lee, Z. Wang, Q. Chu, P.C. Mack, Y. Cheng, J. Duan, Y. Fan, B. Han, Z. Hui, A. Liu, J. Liu, Y. Lu, Z. Ma, M. Shi, Y. Shu, Q. Song, X. Song, Y. Song, C. Wang, X. Wang, Z. Wang, Y. Xu, Y. Yao, L. Zhang, M. Zhao,
    ESMO Open.2022; 7(1): 100395.     CrossRef
  • Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
    Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
    Journal of Personalized Medicine.2022; 12(10): 1651.     CrossRef
  • Predictors for survival in patients with bone metastasis of small cell lung cancer
    MingFeng Xue, Gang Chen, XingGuang Chen, JunYu Hu
    Medicine.2021; 100(34): e27070.     CrossRef
  • Advances in systemic therapy for non-small cell lung cancer
    Meagan Miller, Nasser Hanna
    BMJ.2021; : n2363.     CrossRef
  • Genetic Markers in Lung Cancer Diagnosis: A Review
    Katarzyna Wadowska, Iwona Bil-Lula, Łukasz Trembecki, Mariola Śliwińska-Mossoń
    International Journal of Molecular Sciences.2020; 21(13): 4569.     CrossRef
  • Exploration of estrogen receptor‑associated hub genes and potential molecular mechanisms in non‑smoking females with lung adenocarcinoma using integrated bioinformatics analysis
    Hao Wang, Zhihong Zhang, Ke Xu, Song Wei, Lailing Li, Lijun Wang
    Oncology Letters.2019;[Epub]     CrossRef
  • 9,284 View
  • 381 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Chang-Min Choi, Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Boram Lee, Young-Joo Won, Young-Chul Kim
Cancer Res Treat. 2019;51(4):1400-1410.   Published online February 25, 2019
DOI: https://doi.org/10.4143/crt.2018.704
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea.
Materials and Methods
The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry, and surveyed about 10% of lung cancer cases. For this first survey of cases diagnosed in 2014, cases were selected through a systematic sampling method.
Results
Total 2,621 lung cancer patients were surveyed, and the median patient age was 70 years. During the study period, adenocarcinoma was the most frequent histologic type, the proportion of female patients was 28.4%, and women had a better prognosis (median survival, not reached vs. 13 months; p<0.001) than did men for non-small cell lung cancer. The proportion of never-smokers was 36.4%, and never-smoking was more prevalent in women than in men (87.5 vs. 16.0%, p<0.001). Epidermal growth factor receptor (EGFR) mutations were found in 36.8% of stage IV adenocarcinoma patients, and higher in female compared to male patients (51.2 vs. 26.6%, p<0.001). In addition, patients with EGFR mutation showed better survival (median survival, 18 vs. 8 months; p<0.001) than patients without EGFR mutation in these patients.
Conclusion
This is the first survey to gather unbiased nationwide lung cancer statistics in Korea. More than one-third of lung cancer patients had no smoking history. Female had a high proportion of non-smoker, more adenocarcinoma with EGFR mutation and generally better prognosis than male.

Citations

Citations to this article as recorded by  
  • Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
    Fuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, Satoshi Wasamoto, Yoshiaki Nagai, Takayuki Kishikawa, Yosuke Miura, Akihiro Ono, Yutaka Yamada, Ken Masubuchi, Takashi Osaki, Junichi Nakagawa, Yukihiro Umeda, Hiroyuki Minemura, Yuki Kozu, Hirokazu Tanigu
    Oncology.2024; 102(1): 30.     CrossRef
  • Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients
    Siyao Mai, Haiqing Liu, Hong Zeng, Ziliang Cheng, Jingwen Huang, Guangzi Shi, Yong Li, Zhuo Wu
    Thoracic Cancer.2024; 15(12): 1017.     CrossRef
  • Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
    Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
    Cancer Medicine.2024;[Epub]     CrossRef
  • Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea
    Youn Huh, Yeo Ju Sohn, Hae-Rim Kim, Hyejin Chun, Hwa Jung Kim, Ki Young Son, Dong Keon Yon
    PLOS ONE.2024; 19(5): e0300389.     CrossRef
  • Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes
    In Young Cho, Yoosoo Chang, Eunju Sung, Boyoung Park, Jae-Heon Kang, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
    Cancer & Metabolism.2024;[Epub]     CrossRef
  • Mitochondrial Dynamics in Non-Small Cell Lung Cancer
    Agata Dutkowska, Daria Domańska-Senderowska, Karolina H. Czarnecka-Chrebelska, Ewa Pikus, Aleksandra Zielińska, Laura Biskup, Agata Kołodziejska, Paulina Madura, Maria Możdżan, Urszula Załuska, Edward Zheng, Eliza Adamczyk, Konrad Kędzia, Szymon Wcisło, M
    Cancers.2024; 16(16): 2823.     CrossRef
  • Gender‐specific outcomes of low‐dose computed tomography screening for lung cancer detection: A retrospective study in Chinese never‐smoker population
    Huihong Wang, Jicheng Xie, Yahong Chen, Jiang Jin, Meixian Zhang, TaoHsin Tung, Youzu Xu
    Cancer Medicine.2024;[Epub]     CrossRef
  • Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
    Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
    Scientific Reports.2024;[Epub]     CrossRef
  • Prognostic value of electronic health records-based frailty measures for all-cause mortality in older patients with non-small cell lung cancer
    Minh-Thao Tu, Thi-Ngoc Tran, Hoejun Kwon, Yoon-Jung Choi, Youngjoo Lee, Hyunsoon Cho
    Journal of Geriatric Oncology.2024; : 102130.     CrossRef
  • Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
    Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung
    Cancer Research and Treatment.2023; 55(1): 103.     CrossRef
  • Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
    Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
    Thoracic Cancer.2023; 14(4): 363.     CrossRef
  • Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database
    Min-Hyung Kim, Sojung Park, Yu Rang Park, Wonjun Ji, Seul-Gi Kim, Minji Choo, Seung-Sik Hwang, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi
    BMC Medical Informatics and Decision Making.2023;[Epub]     CrossRef
  • Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
    Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim
    Radiotherapy and Oncology.2023; 183: 109572.     CrossRef
  • A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
    Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
    Cancers.2023; 15(5): 1606.     CrossRef
  • All-round counterattack to conquer lung cancer
    Seung Hun Jang
    Journal of the Korean Medical Association.2023; 66(3): 154.     CrossRef
  • Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
    Tae Hoon Lee, Joo-Hyun Chung, Hong-Gyun Wu, Suzy Kim, Joo Ho Lee, Bhumsuk Keam, Jin-Soo Kim, Ki Hwan Kim, Byoung Hyuck Kim, Hak Jae Kim
    Cancer Research and Treatment.2023; 55(3): 875.     CrossRef
  • Lung Cancer Screening in Asia: An Expert Consensus Report
    David Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, Samina Park, Daniel S.W. Tan, Navneet Singh, Seung Hun Jang, Varut Vardhanabhuti, Antonio B. Ramos, Tomio Nakayama, Nguyen Viet Nhung, Kazuto Ashizawa, Yeun-Chung Chang, Jamsak Tscheikuna, Cong Cung Van,
    Journal of Thoracic Oncology.2023; 18(10): 1303.     CrossRef
  • New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment
    Peiyao Wang, Sophie Sun, Stephen Lam, William W. Lockwood
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
    Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim
    Cancer Research and Treatment.2023; 55(4): 1171.     CrossRef
  • Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
    Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
    JMIR Medical Informatics.2023; 11: e47859.     CrossRef
  • Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer
    Bin Hwangbo, Eun Young Park, Bumhee Yang, Geon Kook Lee, Tae Sung Kim, Hyae Young Kim, Moon Soo Kim, Jong Mog Lee
    Chest.2022; 161(5): 1382.     CrossRef
  • Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging
    Yu Jin Lim, Changhoon Song, Hak Jae Kim
    Radiation Oncology.2022;[Epub]     CrossRef
  • Lung Cancer Screening with Low-Dose Chest Computed Tomography
    Yeon Wook Kim
    The Korean Journal of Medicine.2022; 97(1): 42.     CrossRef
  • Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
    Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2022; 13(9): 1349.     CrossRef
  • Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
    Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    Scientific Reports.2022;[Epub]     CrossRef
  • Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
    Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
    BMC Pulmonary Medicine.2022;[Epub]     CrossRef
  • Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population
    Da Som Jeon, Jin Woo Kim, Seul Gi Kim, Hyeong Ryul Kim, Si Yeol Song, Jae Cheol Lee, Wonjun Ji, Chang‐Min Choi, Ho Cheol Kim
    Thoracic Cancer.2022; 13(18): 2584.     CrossRef
  • Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma
    Yong Xu, Yao Wang, Leilei Liang, Nan Song
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
    Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(4): 444.     CrossRef
  • Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
    Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi
    Cancer Research and Treatment.2021; 53(1): 104.     CrossRef
  • A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
    Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
    Cancer Research and Treatment.2021; 53(1): 93.     CrossRef
  • Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
    Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sun Ah Baek, Sook Kyung Do, Jeong Eun Lee, Jongmoo Park, Seung Soo Yoo, Sunha Choi, Kyung Min Shin, Ji Yun Jeong, Jae Yong Park
    Thoracic Cancer.2021; 12(6): 874.     CrossRef
  • Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients
    Joon Young Choi, Wonjun Ji, Chang-Min Choi, Chaeuk Chung, Jae Myoung Noh, Cheol-Kyu Park, In-Jae Oh, Hong In Yoon, Hyeong Ryul Kim, Ho Young Kim, Chang Dong Yeo, Seung Hun Jang
    Tuberculosis and Respiratory Diseases.2021; 84(2): 105.     CrossRef
  • Recent Trends of Lung Cancer in Korea
    Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
    Tuberculosis and Respiratory Diseases.2021; 84(2): 89.     CrossRef
  • Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
    Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(10): 1598.     CrossRef
  • Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
    Zezhou Wang, Miao Mo, Changming Zhou, Xiaoshuang Feng, Jie Shen, Ting Ye, Yang Zhang, Hong Hu, Haiquan Chen, Ying Zheng
    Thoracic Cancer.2021; 12(11): 1699.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
    Fernando Franco, Enric Carcereny, Maria Guirado, Ana L. Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel del Barco, Oscar Juan, Francisco Aparisi, Jose L. González-Larriba, Manuel Domine, Jose M. Trigo, Manuel Cobo, Sara C
    PLOS ONE.2021; 16(6): e0251761.     CrossRef
  • Survival Prediction of Lung Cancer Using Small-Size Clinical Data with a Multiple Task Variational Autoencoder
    Thanh-Hung Vo, Guee-Sang Lee, Hyung-Jeong Yang, In-Jae Oh, Soo-Hyung Kim, Sae-Ryung Kang
    Electronics.2021; 10(12): 1396.     CrossRef
  • Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry
    I. Re Heo, Ho Cheol Kim, Seung Jun Lee, Jung‐Wan Yoo, Sunmi Ju, Yi Yeong Jeong, Jong Deog Lee, Yu Ji Cho, Jong Hwan Jeong, Manbong Heo, Seung Woo Jung, Tae Hoon Kim
    Thoracic Cancer.2021; 12(18): 2478.     CrossRef
  • Lung Cancer in Korea
    Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
    Journal of Thoracic Oncology.2021; 16(12): 1988.     CrossRef
  • Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns
    Yan-mei Dong, Li-da Qin, Yi-fan Tong, Qi-en He, Ling Wang, Kai Song
    PeerJ.2020; 8: e8349.     CrossRef
  • Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
    Seongho Park, Yoo‐Duk Choi, Jieun Kim, Bo‐Gun Kho, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2020; 11(2): 408.     CrossRef
  • Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
    Eunhyang Park, Hyo Sup Shim
    Cancer Research and Treatment.2020; 52(2): 543.     CrossRef
  • A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment
    Qien He, Zhewei Qiu, Yifan Tong, Kai Song
    IEEE Access.2020; 8: 89031.     CrossRef
  • Épidémiologie des cancers du poumon en France : les tendances actuelles
    E. Giroux Leprieur, A. Vergnenègre, J. Trédaniel
    Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S6.     CrossRef
  • Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
    Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
    European Respiratory Journal.2020; 56(5): 2000177.     CrossRef
  • Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
    Ji Soo Park, Beodeul Kang, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Minkyu Jung, Seung Hoon Beom, Sang Joon Shin, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Joong Bae Ahn, Nam Kyu Kim, Tae Il Kim
    Journal of Cancer Prevention.2019; 24(1): 48.     CrossRef
  • Épidémiologie des cancers du poumon en France: les tendances actuelles
    A. Vergnenègre, J. Trédaniel, L. Bigay-Gamé, O. Bylicki, J-C. Pairon, T. Urban, M. Colonna
    Revue des Maladies Respiratoires Actualités.2019; 11(3): 169.     CrossRef
  • 12,019 View
  • 537 Download
  • 51 Web of Science
  • 49 Crossref
Close layer
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Cancer Res Treat. 2019;51(2):502-509.   Published online June 13, 2018
DOI: https://doi.org/10.4143/crt.2018.117
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib.
Materials and Methods
We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016.
Results
In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months).
Conclusion
First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.

Citations

Citations to this article as recorded by  
  • Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
    Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
    BMC Cancer.2024;[Epub]     CrossRef
  • A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
    BMC Cancer.2024;[Epub]     CrossRef
  • Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
    Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo
    Journal of Thoracic Oncology.2024; 19(7): 973.     CrossRef
  • Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
    Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment
    Noha Ryad, Ayman Abo Elmaaty, Ibrahim M Ibrahim, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Rasha Mohammed Saleem, Islam Zaki, Lina M A Abdel Ghany
    Future Medicinal Chemistry.2024; 16(11): 1087.     CrossRef
  • Lung cancer and pregnancy
    A. L. Chernyshova, A. A. Chernyakov, Ju. M. Trushjuk, O. S. Dil, A. E. Chernyshova
    PULMONOLOGIYA.2024; 34(4): 544.     CrossRef
  • Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation
    Chunhong Chu, Huixia Xu, Chenxue Liu, Xiangkai Wei, Lanxin Li, Rui Wang, Wenrui Cui, Guoliang Zhang, Chenyang Liu, Ke Wang, Lei An, Fei He
    Current Research in Toxicology.2024; 7: 100194.     CrossRef
  • Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies
    Noha Ryad, Ayman Abo Elmaaty, Samy Selim, Mohammed S. Almuhayawi, Soad K. Al Jaouni, Mohamed S. Abdel-Aziz, Arwa Sultan Alqahtani, Islam Zaki, Lina M. A. Abdel Ghany
    RSC Advances.2024; 14(46): 34005.     CrossRef
  • Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
    Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, Hye Ryun Kim
    Drugs - Real World Outcomes.2023; 10(1): 131.     CrossRef
  • Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
    Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
    Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone
    Pharmaceutics.2023; 15(4): 1252.     CrossRef
  • Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
    Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
    Cancers.2023; 15(11): 3015.     CrossRef
  • Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
    Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chávez-Tapia, Emilio Conde-Flores, Andrés F. Cardona, Oscar Arrieta
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Design and Synthesis of Novel Pyrazolopyrimidine Candidates As Promising EGFR-T790M Inhibitors and Apoptosis Inducers
    Ahmed A Gaber, Marwa Sharaky, Ayman Abo Elmaaty, Mohamed M Hammouda, Ahmed AE Mourad, Samy Y Elkhawaga, Mahmoud Mohamed Mokhtar, Amr S Abouzied, Mai AE Mourad, Ahmed A Al-Karmalawy
    Future Medicinal Chemistry.2023; 15(19): 1773.     CrossRef
  • Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
    Huang‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang
    Thoracic Cancer.2023; 14(32): 3208.     CrossRef
  • Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
    Huang‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang
    Thoracic Cancer.2023; 14(32): 3217.     CrossRef
  • Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
    Shidi Xu, Zhihui Zhou, Jie He, Jiaojiao Guo, Xiaoling Huang, Yufeng An, Qingshan Pan, Shan Xu, Wufu Zhu
    Archiv der Pharmazie.2023;[Epub]     CrossRef
  • Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
    Sarbjit Singh, Divya Utreja, Vimal Kumar
    Medicinal Chemistry Research.2022; 31(1): 1.     CrossRef
  • The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
    Cancer Research and Treatment.2022; 54(2): 434.     CrossRef
  • Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
    Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu, John Chang
    Cancers.2022; 14(3): 674.     CrossRef
  • Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
    Cancers.2022; 14(4): 977.     CrossRef
  • Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma
    Martin Zapata Laguado, Andrea Zuluaga, Rafael Parra Medina, Ricardo Bruges
    Cureus.2022;[Epub]     CrossRef
  • Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
    Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang
    Journal of Medicinal Chemistry.2022; 65(6): 4709.     CrossRef
  • Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives
    Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
    Research Journal of Pharmacy and Technology.2022; : 1598.     CrossRef
  • Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Rong Liu, Jianying Zhou, Xia Ling
    Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
  • Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study
    Ping Shi, Xin Jiang, Ye Tao, Ting Li, Xin Li, Chenjing Wang, Yanping Liu, Yaping Ma, Xiaomeng Gao, Yu Cao
    Clinical Pharmacology in Drug Development.2022; 11(10): 1177.     CrossRef
  • Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis
    Bolin Hou, Haiwen Huang, Yueqian Li, Jingnan Liang, Zhijun Xi, Xuejun Jiang, Ling Liu, Erwei Li
    Cell Death Discovery.2022;[Epub]     CrossRef
  • Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
    Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
    Bioorganic Chemistry.2022; 128: 106057.     CrossRef
  • Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
    Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou, Soha H. Emam
    Journal of Enzyme Inhibition and Medicinal Chemistry.2022; 37(1): 2644.     CrossRef
  • Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
    Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
    Scientific Reports.2022;[Epub]     CrossRef
  • Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
    Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
    The Oncologist.2021; 26(4): 281.     CrossRef
  • Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
    Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
    Thoracic Cancer.2021; 12(4): 444.     CrossRef
  • Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
    Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
    Cancer Research and Treatment.2021; 53(2): 457.     CrossRef
  • Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
    Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
    Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, Emir Celik, Deniz Tataroglu Ozyukseler, Murat Ayhan, Tugba Basoglu, Aysegul Ilhan, Nadiye Akdeniz, Ahmet Gulmez, Izzet Dogan, Burak Yasin Aktas, Mustafa Gurbuz, Sinan Koca, Semra Paydas, Ali Murat Tatli
    Journal of Cancer Research and Clinical Oncology.2021; 147(7): 2145.     CrossRef
  • Gefitinib reduces oocyte quality by disturbing meiotic progression
    Hong-Yong Zhang, Ying-Chun Ouyang, Jian Li, Chun-Hui Zhang, Wei Yue, Tie-Gang Meng, Heide Schatten, Qing-Yuan Sun, Wei-Ping Qian
    Toxicology.2021; 452: 152705.     CrossRef
  • Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
    Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet, Koen Deschepper, Annelies Janssens, Daniella Galdermans, Thierry Pieters
    Drugs - Real World Outcomes.2021; 8(2): 141.     CrossRef
  • Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, Yongfeng Yu
    Advances in Therapy.2021; 38(5): 2038.     CrossRef
  • PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
    Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang
    OncoTargets and Therapy.2021; Volume 14: 2301.     CrossRef
  • Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
    Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C - H Yang
    Future Oncology.2021; 17(18): 2395.     CrossRef
  • The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
    Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
    Scientific Reports.2021;[Epub]     CrossRef
  • Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
    Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
    Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
    BMC Cancer.2021;[Epub]     CrossRef
  • Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
    Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
    Cancer Medicine.2021; 10(17): 5809.     CrossRef
  • Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
    Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
    Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
    Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters, Elisa Giovannetti
    Critical Reviews in Oncology/Hematology.2021; 166: 103454.     CrossRef
  • Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
    Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
    Biology.2021; 10(10): 1054.     CrossRef
  • Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
    Yamin Shu, Qilin Zhang, Xucheng He, Li Chen
    Cancer Management and Research.2021; Volume 13: 8297.     CrossRef
  • Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen, Wei Liu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • EFIKASI TERAPI EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKIs) PADA KANKER PARU
    Fitri Wulandari, Widyaningrum Utami, Evieta Rohana, Wimzy Rizqy Prabhata
    Generics: Journal of Research in Pharmacy.2021;[Epub]     CrossRef
  • Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan
    Yao‐Yu Hsieh, Wei‐Tse Fang, Yu‐Wen Lo, Yi‐Han Chen, Li‐Nien Chien
    International Journal of Cancer.2020; 147(4): 1107.     CrossRef
  • Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
    James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim
    Journal of Thoracic Oncology.2020; 15(5): 803.     CrossRef
  • Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines
    Chao Wang, Xiao-Wen Liu, Ting Xiao, Zhi-Qiang Xu, Shuang Cao, Hai-Feng Wang, Qiong-Jiao Yan, Shuang-Xi Gu, Yuan-Yuan Zhu
    Medicinal Chemistry Research.2020; 29(5): 910.     CrossRef
  • Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
    Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong
    Acta Pharmacologica Sinica.2020; 41(10): 1366.     CrossRef
  • Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
    Giulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, Alice Avancini, Ilaria Trestini, Emanuele Vita, Daniela Tregnago, Jessica Menis, Emilio Bria, Michele Milella, Sara Pilotto
    Expert Review of Anticancer Therapy.2020; 20(7): 531.     CrossRef
  • Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study
    Ye Jiang, Wenli Chen, Weiguang Yu, Ning Shi, Guowei Han, Shuai Mao, Xinlei Zhang, Meiji Chen
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
    Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
    Thoracic Cancer.2020; 11(11): 3346.     CrossRef
  • Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
    Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li
    Thoracic Cancer.2019; 10(6): 1461.     CrossRef
  • Afatinib/gefitinib

    Reactions Weekly.2019; 1753(1): 17.     CrossRef
  • Current Approaches in NSCLC Targeting K-RAS and EGFR
    Veronica Aran, Jasminka Omerovic
    International Journal of Molecular Sciences.2019; 20(22): 5701.     CrossRef
  • Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
    Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch
    Future Oncology.2019; 15(13): 1493.     CrossRef
  • Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer
    Future Oncology.2018; 14(27): 2861.     CrossRef
  • 11,892 View
  • 800 Download
  • 72 Web of Science
  • 64 Crossref
Close layer
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):493-501.   Published online June 18, 2018
DOI: https://doi.org/10.4143/crt.2018.125
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).
Materials and Methods
From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status.
Results
Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFR mutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression.
Conclusion
EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.

Citations

Citations to this article as recorded by  
  • Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
    Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
    Lung Cancer.2024; 187: 107414.     CrossRef
  • Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Huan-Wei Liang, Yang Liu, Xin-Bin Pan
    Aging.2024;[Epub]     CrossRef
  • Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
    Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura,
    Cancer Science.2024; 115(4): 1273.     CrossRef
  • Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anast
    Journal of Thoracic Oncology.2024; 19(6): 928.     CrossRef
  • Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
    David J. Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
    Current Oncology.2024; 31(3): 1600.     CrossRef
  • Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
    Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduard
    New England Journal of Medicine.2024; 391(7): 585.     CrossRef
  • Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
    S. Lu, M.-J. Ahn, T. Reungwetwattana, M. Özgüroğlu, T. Kato, J.C.-H. Yang, M. Huang, F. Fujiki, T. Inoue, L.-V. Quang, V. Sriuranpong, D. Vicente, C. Fuentes, A.A. Chaudhry, L. Poole, E. Armenteros Monterroso, Y. Rukazenkov, T. van der Gronde, S.S. Ramali
    Annals of Oncology.2024;[Epub]     CrossRef
  • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy
    Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-we Kim, Hyeong-ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4243.     CrossRef
  • Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study
    Nan Bi, Kunpeng Xu, Hong Ge, Ming Chen, Mingyan E, Li Zhang, Jianzhong Cao, Xu Zhang, Xiao Ding, Bing Xia, Lujun Zhao, Lijie Han, Jiancheng Li, Chen Hu, Luhua Wang
    Journal of the National Cancer Center.2023; 3(1): 65.     CrossRef
  • Locally Advanced Lung Cancer
    Sarah Oh, George N. Botros, Milan Patel, Missak Haigentz, Eshan Patel, Iaonnis Kontopidis, John Langenfeld, Matthew P. Deek, Salma K. Jabbour
    Hematology/Oncology Clinics of North America.2023; 37(3): 533.     CrossRef
  • Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
    Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji
    Thoracic Cancer.2023; 14(15): 1355.     CrossRef
  • EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
    Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
    Cancer Research and Treatment.2023; 55(2): 498.     CrossRef
  • Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
    Yang Liu, Huan-Wei Liang, Xin-Bin Pan
    Aging.2023;[Epub]     CrossRef
  • Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
    Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
    Thoracic Cancer.2022; 13(2): 182.     CrossRef
  • Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
    Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
    Cancer Science.2022; 113(1): 205.     CrossRef
  • An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
    Po-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, Te-Chun Hsia, Meng-Chih Lin, Min-Hsi Lin, Jin-Yuan Shih, Cheng-Ta Yang, Sheng-Hsiung Yang, Yuh-Min Chen
    JTO Clinical and Research Reports.2022; 3(3): 100292.     CrossRef
  • Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
    Yuxiang Wang, Wenjuan Yu, Jian Shi, Rong Qiu, Nan Jiang, Zhuofan Wang, Jie Yang, Zhongfei Jia, Meng Song
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
    Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion
    Yoonki Hong, Sunmin Park, Myoung Kyu Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
    D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
    Meditsinskiy sovet = Medical Council.2022; (22): 12.     CrossRef
  • Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
    Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang
    Thoracic Cancer.2021; 12(6): 814.     CrossRef
  • Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Hea
    Journal of Thoracic Oncology.2021; 16(6): 1030.     CrossRef
  • Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren
    Mazen A. Juratli, Benjamin Struecker, Shadi Katou, M. Haluk Morguel, Andreas Pascher
    Der Chirurg.2021; 92(11): 1003.     CrossRef
  • Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Sonam Puri, Andreas Saltos, Bradford Perez, Xiuning Le, Jhanelle E. Gray
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
    Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
    Lung Cancer.2020; 146: 23.     CrossRef
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    Connor O’Leary, Harry Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Ken J. O’Byrne
    Pharmaceuticals.2020; 13(10): 273.     CrossRef
  • MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
    Noor Altaleb
    Clinical Cancer Drugs.2020; 7(2): 65.     CrossRef
  • Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
    Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn, Hojoong Kim
    Lung Cancer.2019; 129: 28.     CrossRef
  • A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm
    Wang-Yu Zhu, Ke-xin Fang, Jian-ying He, Ri Cui, Yong-Kui Zhang, Han-bo Le
    Disease Markers.2019; 2019: 1.     CrossRef
  • 12,720 View
  • 454 Download
  • 27 Web of Science
  • 29 Crossref
Close layer
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018
DOI: https://doi.org/10.4143/crt.2018.151
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established.
Materials and Methods
Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy.
Results
Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response.
Conclusion
The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.

Citations

Citations to this article as recorded by  
  • Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
    Clinical Lung Cancer.2024; 25(2): 100.     CrossRef
  • Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
    Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
    BMC Proceedings.2024;[Epub]     CrossRef
  • Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
    Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu
    Lung Cancer.2024; 191: 107798.     CrossRef
  • The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
    Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
    Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
    Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865.     CrossRef
  • Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
    Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
    Lung Cancer.2023; 179: 107186.     CrossRef
  • EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
    Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
    Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365.     CrossRef
  • EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
    Qianming Bai, Jialei Wang, Xiaoyan Zhou
    Cancer Treatment Reviews.2023; 120: 102605.     CrossRef
  • A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
    Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
    Cancer Treatment Reviews.2023; 120: 102628.     CrossRef
  • Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
    Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
    Thoracic Cancer.2023; 14(33): 3247.     CrossRef
  • Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
    Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
    Anti-Cancer Drugs.2022; 33(4): 406.     CrossRef
  • Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
    Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
    CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731.     CrossRef
  • Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
    Timothée Olivier, Vinay Prasad
    Translational Oncology.2022; 23: 101475.     CrossRef
  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
    Cancer Cell.2022; 40(7): 754.     CrossRef
  • EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
    Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
    Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
    Journal of Modern Oncology.2022; 24(3): 340.     CrossRef
  • Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
    Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
    Journal of Clinical Medicine.2022; 12(1): 112.     CrossRef
  • Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
    Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
    Lung Cancer.2021; 152: 39.     CrossRef
  • Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
    Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
    PLOS ONE.2021; 16(3): e0247620.     CrossRef
  • Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
    Clinical Cancer Research.2021; 27(10): 2920.     CrossRef
  • EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
    Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
    Clinical Lung Cancer.2021; 22(6): e859.     CrossRef
  • Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
    Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
    Cancer Discovery.2021; 11(7): 1688.     CrossRef
  • Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
    Scientific Reports.2021;[Epub]     CrossRef
  • EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
    Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
    Cancers.2021; 13(20): 5132.     CrossRef
  • Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
    JAMA Oncology.2021; 7(12): e214761.     CrossRef
  • A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
    Targeted Oncology.2021; 16(6): 801.     CrossRef
  • External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
    Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
    Pathology & Oncology Research.2020; 26(3): 1595.     CrossRef
  • Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
    Lung Cancer.2020; 141: 9.     CrossRef
  • EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
    Lung Cancer.2020; 145: 186.     CrossRef
  • Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
    YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
    Molecular Oncology.2020; 14(8): 1695.     CrossRef
  • The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
    Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
    Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
    Lung Cancer.2020; 149: 53.     CrossRef
  • Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
    Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
    Clinical Lung Cancer.2019; 20(6): e620.     CrossRef
  • Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
    BMC Cancer.2019;[Epub]     CrossRef
  • Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
    Ya Gao, Wies R. Vallentgoed, Pim J. French
    Cancers.2018; 10(12): 489.     CrossRef
  • 15,596 View
  • 691 Download
  • 43 Web of Science
  • 36 Crossref
Close layer
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):718-726.   Published online September 3, 2018
DOI: https://doi.org/10.4143/crt.2018.324
AbstractAbstract PDFPubReaderePub
Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Citations

Citations to this article as recorded by  
  • Osimertinib with Chemotherapy in EGFR -Mutated NSCLC

    New England Journal of Medicine.2024; 390(5): 478.     CrossRef
  • Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
    Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
    Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87.     CrossRef
  • Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
    Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
    Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
    JAMA Oncology.2022; 8(6): 879.     CrossRef
  • Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
    Oncology Letters.2022;[Epub]     CrossRef
  • Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
    Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Lung Cancer.2021; 152: 15.     CrossRef
  • Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
    Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
    PLOS ONE.2021; 16(9): e0255133.     CrossRef
  • Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
    Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
    Lung Cancer.2021; 162: 169.     CrossRef
  • Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
    Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
    Current Oncology.2021; 28(6): 4894.     CrossRef
  • Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
    Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
    Journal of Chemotherapy.2020; 32(8): 429.     CrossRef
  • 9,846 View
  • 347 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Eun Kyoung Kim, Jinhyun Cho, Ji-Yeon Kim, Sung-A Chang, Sung-Ji Park, Jin Oh Choi, Sang Chol Lee, Jin Seok Ahn, Seung Woo Park, Young-Hyuck Im, Eun Seok Jeon, Yeon Hee Park
Cancer Res Treat. 2019;51(2):727-736.   Published online September 4, 2018
DOI: https://doi.org/10.4143/crt.2018.262
AbstractAbstract PDFPubReaderePub
Purpose
While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed to investigate the clinical predictors of TRCD in the adjuvant setting of human epidermal growth factor receptor 2–positive breast cancer patients.
Materials and Methods
From August 2003 to April 2016, consecutive 998 patients who were treated with adjuvant trastuzumab for breast cancer were retrospectively evaluated. TRCD was defined as a decrease ≥10% in left ventricular ejection fraction (LVEF), with a decline below the normal limit or symptomatic heart failure.
Results
Among 787 eligible patients who had complete data sets consisting of both baseline and follow-up assessment of left ventricular systolic function by echocardiography (mean age, 49.9±9.5 years), 58 (7.4%) developed TRCD. TRCD patients had lower baseline LVEF (63% [59–66] vs. 65% [61–68], p=0.016) and more frequently administered Adriamycin (98% vs. 89%, p=0.022) than those without TRCD. On follow-up echocardiography, a drop in LVEF ≥5% within the first 3 months was more frequent in TRCD patients (78.3% vs. 38.4%, p<0.001). Regardless of baseline LVEF and Adriamycin treatment, a drop in LVEF ≥5% within the first 3 months of trastuzumab administration was strongly associated with the development of TRCD (adjusted hazard ratio, 45.1[17.0–127.6], p<0.001).
Conclusion
The overall incidence of TRCD was 7.4% in Asian breast cancer patients treated with adjuvant trastuzumab. A decline in LVEF ≥5% within the first 3 months of trastuzumab initiation was strongly associated with TRCD development in patients with breast cancer.

Citations

Citations to this article as recorded by  
  • Noninvasive identification and therapeutic implications of supernormal left ventricular contractile phenotype
    Yi Wang, Lixue Yin
    Exploration of Cardiology.2024; 2(3): 97.     CrossRef
  • ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab
    Xin Liu, Liyuan Tao, Mopei Wang, Haiyan Li, Weixian Xu
    Clinical Breast Cancer.2023; 23(1): 23.     CrossRef
  • New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review
    Alexia Alexandraki, Elisavet Papageorgiou, Marina Zacharia, Kalliopi Keramida, Andri Papakonstantinou, Carlo M. Cipolla, Dorothea Tsekoura, Katerina Naka, Ketti Mazzocco, Davide Mauri, Manolis Tsiknakis, Georgios C. Manikis, Kostas Marias, Yiola Marcou, E
    Cancers.2023; 15(13): 3290.     CrossRef
  • Guidelines in Cardio-Oncology: The Balance Between Evidence and Expert Opinion
    Douglas J. Leedy, Marta Alhama-Belotto, William R. Gwin, Ruchi Kapoor, Elina Minami, Eric J. Chow, Richard K. Cheng
    Current Treatment Options in Cardiovascular Medicine.2023; 25(11): 639.     CrossRef
  • Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
    Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac, Ghazwa B. Korayem
    Cardio-Oncology.2023;[Epub]     CrossRef
  • Lessons learnt in the first year of an Australian pediatric cardio oncology clinic
    Claudia Toro, Ben Felmingham, Mangesh Jhadav, David S. Celermajer, Andre La Gerche, John O’Sullivan, Sanjeev Kumar, Marion K. Mateos, Joy Fulbright, Dinisha Govender, Lane Collier, Michael Cheung, David D. Eisenstat, Peter W. Lange, Julian Ayer, David A.
    Cardio-Oncology.2023;[Epub]     CrossRef
  • Deceleration capacity of heart rate predicts trastuzumab‐related cardiotoxicity in patients with HER2‐positive breast cancer: A prospective observational study
    Yanying Feng, Zhenhua Qin, Zhijun Yang
    Journal of Clinical Pharmacy and Therapeutics.2021; 46(1): 93.     CrossRef
  • Vascular and Cardiac Prognostic Determinants in Patients with Gynecological Cancers: A Six-Year Follow-up Study
    Pietro Scicchitano, Marco Tucci, Gabriella Ricci, Michele Gesualdo, Santa Carbonara, Giuseppe Totaro, Annagrazia Cecere, Rosa Carbonara, Francesca Cortese, Vera Loizzi, Gennaro Cormio, Ettore Cicinelli, Marco Matteo Ciccone
    Applied Sciences.2021; 11(13): 6091.     CrossRef
  • Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours
    Liliana Maria Radulescu, Dan Radulescu, Tudor-Eliade Ciuleanu, Dana Crisan, Elena Buzdugan, Dragos-Mihai Romitan, Anca Dana Buzoianu
    Medicina.2021; 57(8): 806.     CrossRef
  • Successful Use of Digoxin for Trastuzumab-related Cardiotoxicity to Facilitate Breast Surgery in a Patient with Metastatic Breast Cancer
    Tsuyoshi SHIGA, Takako KAMIO, Kenta UTO, Kotaro ARAI
    Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics .2021; 52(4): 101.     CrossRef
  • Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
    Elena Geuna, Pasquale Lombardi, Rossella Martinello, Davide Garino, Alessandro Bonzano, Danilo Galizia, Annamaria Nuzzo, Paola Berchialla, Paolo Becco, Monica Mangioni, Lorena De Zarlo, Filippo Montemurro
    Cancers.2020; 12(2): 327.     CrossRef
  • A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
    Wala Ben Kridis, Syrine Sghaier, Salma Charfeddine, Nabil Toumi, Jamel Daoud, Samir Kammoun, Afef Khanfir
    American Journal of Clinical Oncology.2020; 43(7): 510.     CrossRef
  • Examining Cardiotoxicity With HER2 Therapies
    Neelima Denduluri
    JACC: CardioOncology.2020; 2(2): 176.     CrossRef
  • Determinants of left ventricular ejection fraction and a novel method to improve its assessment of myocardial contractility
    Manuel Ignacio Monge García, Zhongping Jian, Jos J. Settels, Charles Hunley, Maurizio Cecconi, Feras Hatib, Michael R. Pinsky
    Annals of Intensive Care.2019;[Epub]     CrossRef
  • The Role of Echocardiography in Cardio-oncology Patients: Contemporary Indications and Future Directions
    Saiuj Bhat, Nestor Gahungu, Paaladinesh Thavendiranathan, Girish Dwivedi
    Current Cardiovascular Imaging Reports.2019;[Epub]     CrossRef
  • Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
    Zhuyu Xu, Dandan Guo, Zhongliang Jiang, Rongsheng Tong, Peidu Jiang, Lan Bai, Lu Chen, Yuxuan Zhu, Chun Guo, Jianyou Shi, Dongke Yu
    European Journal of Medicinal Chemistry.2019; 183: 111682.     CrossRef
  • 9,713 View
  • 256 Download
  • 16 Web of Science
  • 16 Crossref
Close layer
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji-Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young-Hyuck Im, Jong Han Yu, Yeon Hee Park
Cancer Res Treat. 2019;51(2):737-747.   Published online September 5, 2018
DOI: https://doi.org/10.4143/crt.2018.342
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.
Materials and Methods
A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.
Results
In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).
Conclusion
A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

Citations

Citations to this article as recorded by  
  • PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study
    Judith Katharina Ballé, Martina Vetter, Tariku Wakuma Kenea, Pia Eber-Schulz, Christian Reibold, Hannes-Viktor Ziegenhorn, Kathrin Stückrath, Claudia Wickenhauser, Adamu Addissie, Pablo Santos, Eva Johanna Kantelhardt, Sefonias Getachew, Marcus Bauer
    BMC Cancer.2024;[Epub]     CrossRef
  • Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Eun Hye Joo, Sangmin Kim, Donghyun Park, Taeseob Lee, Woong-Yang Park, Kyung Yeon Han, Jeong Eon Lee
    International Journal of Molecular Sciences.2024; 25(11): 5876.     CrossRef
  • Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer
    Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song
    Cancer.2024; 130(S8): 1435.     CrossRef
  • Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
    Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins
    International Journal of Molecular Sciences.2024; 25(5): 2616.     CrossRef
  • iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data
    Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer
    Bioinformatics Advances.2024;[Epub]     CrossRef
  • Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification
    Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
    Diagnostics.2024; 14(6): 660.     CrossRef
  • Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study
    Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing
    JCI Insight.2024;[Epub]     CrossRef
  • Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
    Katerina S. Grechukhina, Daria A. Filonenko, Margarita V. Sukhova, Liudmila G. Zhukova
    Journal of Modern Oncology.2024; 26(2): 182.     CrossRef
  • Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study
    Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
    BMC Cancer.2024;[Epub]     CrossRef
  • Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data
    Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu
    Cells.2023; 12(3): 367.     CrossRef
  • Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes
    Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li
    IEEE Access.2023; 11: 10912.     CrossRef
  • Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
    Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte
    Breast Cancer Research and Treatment.2023; 199(1): 1.     CrossRef
  • A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer
    Mehdi Hamaneh, Yi-Kuo Yu
    Cancer Informatics.2023;[Epub]     CrossRef
  • XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data
    Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar
    Expert Systems with Applications.2023; 225: 120130.     CrossRef
  • XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes
    Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar
    Biomedical Signal Processing and Control.2023; 84: 104979.     CrossRef
  • The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
    Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
    Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella
    Cancers.2022; 14(3): 512.     CrossRef
  • Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
    Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer
    Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang
    BMC Cancer.2022;[Epub]     CrossRef
  • Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
    Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina
    International Journal of Molecular Sciences.2022; 23(15): 8716.     CrossRef
  • The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?
    Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo
    Critical Reviews in Oncology/Hematology.2022; : 103781.     CrossRef
  • Prognostic factors and molecular subtypes in young women with breast cancer
    Yasmin Shukair, Rafaela Veiga Monteiro
    Mastology.2022;[Epub]     CrossRef
  • Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies
    Haruko Takahashi, Daisuke Kawahara, Yutaka Kikuchi
    Cancers.2022; 14(17): 4080.     CrossRef
  • Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection
    Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee
    Cancers.2022; 14(17): 4120.     CrossRef
  • Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
    Yingying Xu, Yonghao Liang, Guanghao Yin
    Clinical and Translational Oncology.2022; 25(4): 1024.     CrossRef
  • Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
    Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel,
    JAMA Network Open.2022; 5(12): e2247154.     CrossRef
  • Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
    Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study
    Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen
    Breast Cancer.2021; 28(6): 1235.     CrossRef
  • Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification
    Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar
    IEEE Access.2021; 9: 103347.     CrossRef
  • Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level
    Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • A single-cell and spatially resolved atlas of human breast cancers
    Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen
    Nature Genetics.2021; 53(9): 1334.     CrossRef
  • Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method
    Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma
    Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo
    Pathology - Research and Practice.2021; 228: 153677.     CrossRef
  • Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets
    Stefania Morganti, Giuseppe Curigliano
    Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7.     CrossRef
  • MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
    Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla
    Breast Cancer Research and Treatment.2020; 180(1): 73.     CrossRef
  • Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape
    Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko
    Cancers.2020; 12(5): 1165.     CrossRef
  • Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
    Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer
    Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes
    Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu
    Aging.2020; 12(13): 13318.     CrossRef
  • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
    Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
  • Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification
    Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich
    Clinical Chemistry.2020; 66(11): 1459.     CrossRef
  • A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data
    Filippo Valle, Matteo Osella, Michele Caselle
    Cancers.2020; 12(12): 3799.     CrossRef
  • Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
    Giuseppe Viale, Elisabetta Munzone
    The Breast.2019; 48: S49.     CrossRef
  • 13,161 View
  • 476 Download
  • 47 Web of Science
  • 44 Crossref
Close layer
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
Kyung Hwa Lee, Yong Chan Ahn, Hongryull Pyo, Jae Myoung Noh, Seung Gyu Park, Tae Gyu Kim, Eonju Lee, Heerim Nam, Hyebin Lee, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
Cancer Res Treat. 2019;51(2):769-776.   Published online September 11, 2018
DOI: https://doi.org/10.4143/crt.2018.366
AbstractAbstract PDFPubReaderePub
Purpose
This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer.
Materials and Methods
Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course.
Results
The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade ≥ 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED10) (≥ 79.2 Gy10 vs. < 79.2 Gy10; hazard ratio [HR], 0.431), smaller CTV (≤ 80 cm3 vs. > 80 cm3; HR, 0.403), and longer disease-free interval (> 1 year vs. ≤ 1 year; HR, 0.489) were significantly favorable factors for OS.
Conclusion
The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED10, smaller CTV, and longer disease-free interval were favorable factors for improved survival.

Citations

Citations to this article as recorded by  
  • Prognosis of non‐small cell lung cancer with postoperative regional lymph node recurrence
    Yoichi Ohtaki, Toshiteru Nagashima, Naoko Okano, Nobuteru Kubo, Takeru Ohtaka, Noriaki Sunaga, Reiko Sakurai, Yosuke Miura, Seshiru Nakazawa, Natsuko Kawatani, Tomohiro Yazawa, Ryohei Yoshikawa, Eiji Narusawa, Ken Shirabe
    Thoracic Cancer.2024; 15(11): 859.     CrossRef
  • Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056)
    Megumi Furuta, Hidehito Horinouchi, Isao Yokota, Teppei Yamaguchi, Shoichi Itoh, Takafumi Fukui, Akira Iwashima, Jun Sugisaka, Yu Miura, Hisashi Tanaka, Taichi Miyawaki, Hiroshi Yokouchi, Keita Miura, Ryota Saito, Go Saito, Tatsuhiko Kamoshida, Yusuke Uch
    Cancer Science.2024;[Epub]     CrossRef
  • Impact of lymphadenectomy extent on immunotherapy efficacy in post-resectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study
    Hongsheng Deng, Juan Zhou, Hualin Chen, Xiuyu Cai, Ran Zhong, Feng Li, Bo Cheng, Caichen Li, Qingzhu Jia, Caicun Zhou, René Horsleben Petersen, Gaetano Rocco, Alex Brunelli, Calvin S.H. Ng, Thomas A. D’Amico, Chunxia Su, Jianxing He, Wenhua Liang, Bo Zhu
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
    Kathleen Bowes, Nick Jovanoski, Audrey E. Brown, Danilo Di Maio, Rossella Belleli, Shkun Chadda, Seye Abogunrin
    Medical Oncology.2022;[Epub]     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)
    NaiBin Chen, QiWen Li, SiYu Wang, Mai Xiong, YiFeng Luo, Bin Wang, Li Chen, MaoSheng Lin, XiaoBo Jiang, JianLan Fang, SuPing Guo, JinYu Guo, Nan Hu, XinLei Ai, DaQuan Wang, Chu Chu, FangJie Liu, Hao Long, JunYe Wang, Bo Qiu, Hui Liu
    Lung Cancer.2021; 156: 82.     CrossRef
  • Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience
    Yoon Young Jo, Su Ssan Kim, Si Yeol Song, Eun Kyung Choi
    Radiation Oncology Journal.2021; 39(3): 210.     CrossRef
  • Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy
    Cole Friedes, Nicholas Mai, Wei Fu, Chen Hu, Peijin Han, Kristen A. Marrone, K. Ranh Voong, Russell K. Hales
    Lung Cancer.2020; 145: 119.     CrossRef
  • 9,259 View
  • 226 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(1):408-412.   Published online May 23, 2018
DOI: https://doi.org/10.4143/crt.2018.138
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.

Citations

Citations to this article as recorded by  
  • Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients
    Hyunjong Lee, Sujin Seo, Sungho Won, Woong-Yang Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
    Scientific Reports.2023;[Epub]     CrossRef
  • Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(1): 188645.     CrossRef
  • Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
    Rashidi Dzul Keflee, Kok Hoong Leong, Satoshi Ogawa, Jerome Bignon, Mun Chiang Chan, Kin Weng Kong
    Biochemical Pharmacology.2022; 205: 115262.     CrossRef
  • Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer
    Zhen Wu, Wei Zhao, Zhen Yang, Yue Ming Wang, Yu Dai, Liang-An Chen
    Cancer Management and Research.2021; Volume 13: 2025.     CrossRef
  • Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
    Hong-Shuai Li, Guang-Jian Yang, Yan Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
    Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
    Cancers.2021; 13(12): 2861.     CrossRef
  • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
    BMB Reports.2021; 54(7): 386.     CrossRef
  • Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
    Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh
    Journal of Medicinal Chemistry.2020; 63(1): 40.     CrossRef
  • Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
    Gahyun Kim, Jinho Kim, Hongui Cha, Woong-Yang Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
    Scientific Reports.2020;[Epub]     CrossRef
  • Afatinib/gefitinib/osimertinib

    Reactions Weekly.2019; 1741(1): 16.     CrossRef
  • Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
    Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yunpeng Liu
    BMC Cancer.2019;[Epub]     CrossRef
  • Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah, Devron R. Shah
    Drug Safety.2019; 42(2): 181.     CrossRef
  • A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC
    Yuanhao Lv, Tingting Du, Ming Ji, Chunyang Wang, Songwen Lin, Nina Xue, Jing Jin, Heng Xu, Xiaoguang Chen
    Journal of Drug Targeting.2018; : 1.     CrossRef
  • 8,993 View
  • 457 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim
Cancer Res Treat. 2017;49(4):880-889.   Published online December 12, 2016
DOI: https://doi.org/10.4143/crt.2016.442
AbstractAbstract PDFPubReaderePub
Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by  
  • The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
    Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
    Medicine.2022; 101(28): e29580.     CrossRef
  • The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
    Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
    Journal of Cancer Research and Therapeutics.2022; 18(7): 1910.     CrossRef
  • 44,076 View
  • 260 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Ji-Yeon Kim, Kyunghee Park, Hae Hyun Jung, Eunjin Lee, Eun Yoon Cho, Kwang Hee Lee, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1338-1350.   Published online February 18, 2016
DOI: https://doi.org/10.4143/crt.2015.430
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
Materials and Methods
We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
Results
Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57,respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patientswith a TP53 missense mutation (5-year distantrecurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
Conclusion
Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.

Citations

Citations to this article as recorded by  
  • Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer
    Rachel Han, Sharon Nofech-Mozes, Dina Boles, Hannah Wu, Nikolina Curcin, Elzbieta Slodkowska
    International Journal of Surgical Pathology.2024; 32(2): 239.     CrossRef
  • Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
    Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez, Luis G. Gu
    Medicina.2024; 60(1): 168.     CrossRef
  • TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation
    Yali Su, Jiaxuan Zhao, Haoran Fu, Zeliang Liu, Panyan Du, Jianxia Zheng, Jinghua Wu, Jinghua Zhang
    Biochemical Pharmacology.2024; 221: 116047.     CrossRef
  • TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
    Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo
    Cancers.2024; 16(6): 1184.     CrossRef
  • Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
    Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
    Journal of Personalized Medicine.2023; 13(2): 190.     CrossRef
  • The role of p53 and ki67 in predicting clinical outcome in breast cancer patients
    Bhanu Prakash Lalkota, B.J Srinivasa, Mani V. Swamy, Diganta Hazarika, B.M Jeet, K Jyothi, Mithua Ghosh, Suhail M. Sayeed, Mohammad Nasiruddin, Radheshyam Naik
    Journal of Cancer Research and Therapeutics.2023; 19(2): 208.     CrossRef
  • Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis
    Xing Chang, Zi Liu, Simeng Cao, Jiang Bian, Dayong Zheng, Nuo Wang, Qi Guan, Yingliang Wu, Weige Zhang, Zengqiang Li, Daiying Zuo
    Toxicology and Applied Pharmacology.2022; 436: 115883.     CrossRef
  • Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer
    Jie Yao, Qian Chen, Jun‐qi Zhu, Rui‐gang Cai
    The Journal of Gene Medicine.2022;[Epub]     CrossRef
  • Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro
    Konrad A. Szychowski, Bartosz Skóra, Tadeusz Pomianek
    Biomedicine & Pharmacotherapy.2022; 151: 113149.     CrossRef
  • p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
    Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
    Cancer Investigation.2022; 40(10): 879.     CrossRef
  • Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer
    Hyo-Jin Kim, Bo-Gyeong Seo, Eun-Chan Seo, Kwang-Min Lee, Cheol Hwangbo
    Current Issues in Molecular Biology.2022; 44(12): 5848.     CrossRef
  • An integrative pan-cancer analysis of COPB1 based on data mining
    Heyan Chen, Kunlong Li, Yijun Li, Peilin Xie, Jianjun He, Huimin Zhang
    Cancer Biomarkers.2021; 30(1): 13.     CrossRef
  • Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma
    Lauren J. Mills, Logan G. Spector, David A. Largaespada, Lindsay A. Williams
    Biology of Sex Differences.2021;[Epub]     CrossRef
  • GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature
    Patrizia Querzoli, Massimo Pedriali, Rosa Rinaldi, Paola Secchiero, Paolo Giorgi Rossi, Elisabetta Kuhn
    Diagnostics.2021; 11(4): 604.     CrossRef
  • Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis
    Dharambir Kashyap, Vivek Kumar Garg, Elise N. Sandberg, Neelam Goel, Anupam Bishayee
    Pharmaceutics.2021; 13(4): 569.     CrossRef
  • Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
    Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing Liu, Han Han-Zhang, Analyn Lizaso, Ning Liao
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Syndrome de Peutz–Jeghers et surveillance mammaire : les nouvelles recommandations à propos d’une observation
    M. Osada, P. Maniez, N. Taris, C. Mathelin
    Gynécologie Obstétrique Fertilité & Sénologie .2021; 49(10): 795.     CrossRef
  • Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
    Reyhaneh Farghadani, Rakesh Naidu
    Cancers.2021; 13(14): 3427.     CrossRef
  • Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases
    Wachiraphan Supsavhad, Bardes B. Hassan, Jessica K. Simmons, Wessel P. Dirksen, Said M. Elshafae, Nicole A. Kohart, Aylin A. Demirer, Thomas J. Rosol
    Veterinary Sciences.2021; 8(8): 153.     CrossRef
  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
    Ashkan Shahbandi, Hoang D. Nguyen, James G. Jackson
    Trends in Cancer.2020; 6(2): 98.     CrossRef
  • The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection
    Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang
    Breast Cancer Research and Treatment.2020; 180(1): 237.     CrossRef
  • Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
    Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu
    Cancer Communications.2020; 40(6): 260.     CrossRef
  • Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer
    Gu Xiao, Devon Lundine, George K. Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L. Donabedian, Thomas Reiner, Galina F. Khramtsova, Olufunmilayo I. Olopade, Alexander Mazo, Jill Bargonetti
    Cancer Research.2020; 80(3): 394.     CrossRef
  • Genomic analysis of racial differences in triple negative breast cancer
    Chang-Sheng Chang, Eiko Kitamura, Joan Johnson, Roni Bollag, Lesleyann Hawthorn
    Genomics.2019; 111(6): 1529.     CrossRef
  • p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Hyeon Jeong Oh, Jeong Mo Bae, Xianyu Wen, Seorin Jung, Younghoon Kim, Kyung Ju Kim, Nam-Yun Cho, Jung Ho Kim, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang
    British Journal of Cancer.2019; 120(8): 797.     CrossRef
  • Immunostaining for p53 and p16CDKN2A Protein Is Not Predictive of Prognosis for Dogs with Malignant Mammary Gland Neoplasms
    John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson
    Veterinary Sciences.2019; 6(1): 34.     CrossRef
  • NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
    Paul B. Mullan, Victoria Bingham, Paula Haddock, Gareth W. Irwin, Elaine Kay, Stephen McQuaid, Niamh E. Buckley
    BMC Cancer.2019;[Epub]     CrossRef
  • Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
    Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang, Li-hua Zheng, Sonali Jindal, Yun-jiang Liu
    Medicine.2019; 98(18): e15449.     CrossRef
  • Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
    Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad
    PLOS ONE.2019; 14(6): e0218030.     CrossRef
  • Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
    Elisabetta Munzone, Kathryn P. Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Aron Goldhirsch, Massimo B
    Breast Cancer Research and Treatment.2018; 170(2): 351.     CrossRef
  • Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo
    Liangjian Xiang, Xiaoyu Xu, Shuo Zhang, Dongyan Cai, Xiaofeng Dai
    Free Radical Biology and Medicine.2018; 124: 205.     CrossRef
  • Genetic Markers in Triple-Negative Breast Cancer
    Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch
    Clinical Breast Cancer.2018; 18(5): e841.     CrossRef
  • Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy‐treated triple negative breast cancer
    Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
    The Kaohsiung Journal of Medical Sciences.2018; 34(12): 663.     CrossRef
  • Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
    Yanli Luo, Wentao Huang, Huizhen Zhang, Guang Liu
    Oncology Letters.2018;[Epub]     CrossRef
  • P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
    Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman
    PLOS ONE.2017; 12(2): e0172324.     CrossRef
  • Alcohol promotes migration and invasion of triple‐negative breast cancer cells through activation of p38 MAPK and JNK
    Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Xiaohe Yang
    Molecular Carcinogenesis.2017; 56(3): 849.     CrossRef
  • Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
    Zongbi Yi, Fei Ma, Chunxiao Li, Rongrong Chen, Lifang Yuan, Xiaoying Sun, Xiuwen Guan, Lixi Li, Binliang Liu, Yanfang Guan, Haili Qian, Binghe Xu
    Scientific Reports.2017;[Epub]     CrossRef
  • TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas
    Táya F. Oliveira, Tábata Maués, Mariana S. Ramundo, Agnes Marie S. Figueiredo, Marcela F. V. de Mello, Kênia B. El-Jaick, Maria de Lourdes G. Ferreira, Ana Maria R. Ferreira
    Journal of Veterinary Diagnostic Investigation.2017; 29(6): 865.     CrossRef
  • Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
    Jisela Dimas-González, Vilma Maldonado-Lagunas, José Díaz-Chávez, María Eugenia López-Arellano, José Muñoz-Camacho, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez
    Oncology Reports.2017; 37(5): 3026.     CrossRef
  • Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing
    Xi-Xi Chen, Qian Zhong, Yang Liu, Shu-Mei Yan, Zhang-Hua Chen, Shan-Zhao Jin, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai, Mu-Sheng Z
    Nature Communications.2017;[Epub]     CrossRef
  • Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
    Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
    Oncotarget.2017; 8(17): 27997.     CrossRef
  • miR-34a expression in human breast cancer is associated with drug resistance
    Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao
    Oncotarget.2017; 8(63): 106270.     CrossRef
  • Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer
    Min Chong Kim, Jung Eun Choi, Soo Jung Lee, Young Kyung Bae
    Annals of Surgical Oncology.2016; 23(11): 3524.     CrossRef
  • 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
    Jingwen Xu, Mengting Han, Jiwei Shen, Qi Guan, Zhaoshi Bai, Binyue Lang, Huijuan Zhang, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu
    Cancer Letters.2016; 383(1): 9.     CrossRef
  • 16,931 View
  • 330 Download
  • 50 Web of Science
  • 44 Crossref
Close layer
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1382-1388.   Published online March 11, 2016
DOI: https://doi.org/10.4143/crt.2015.423
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by  
  • HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
    Kamal Saeed, Shewaz Salih
    JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11.     CrossRef
  • Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
    Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
    Breast Cancer Research and Treatment.2021; 187(3): 785.     CrossRef
  • Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
    Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
    PLOS ONE.2021; 16(12): e0261258.     CrossRef
  • Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
    Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
    The American Journal of Surgery.2020; 220(6): 1417.     CrossRef
  • Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
    Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
    Breast Disease.2018; 37(4): 177.     CrossRef
  • Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
    Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
    Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
    Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
    Annals of Surgical Oncology.2017; 24(10): 2881.     CrossRef
  • Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
    Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
    Medicine.2016; 95(44): e5302.     CrossRef
  • 12,442 View
  • 153 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Insuk Sohn, Won Ho Gil, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2015;47(4):765-773.   Published online January 13, 2015
DOI: https://doi.org/10.4143/crt.2014.168
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the role of regular postoperative surveillance to improve the prognosis of patients with breast cancer after curative surgery. Materials and Methods We retrospectively analyzed the medical records of 4,119 patients who received curative surgery for breast cancer at Samsung Medical Center between January 2000 and September 2008. Patients were divided into two groups (group I, regular postoperative surveillance; group II, control group) according to their post-therapy follow-up status for the first 5 years after surgery. Results Among the 3,770 patients selected for inclusion, groups I and II contained 3,300 (87%) and 470 (13%) patients, respectively. The recurrence rates at 5 years for groups I and II were 10.6% and 16.4%, respectively (hazard ratio, 0.85; 95% confidence interval [CI], 0.67 to 1.09; p=0.197). The 10-year mortality cumulative rates were 8.8% for group I and 25.4% for group II (hazard ratio, 0.28; 95% CI, 0.22 to 0.35; p < 0.001). In multivariate analysis for recurrence-free survival (RFS), age over 40 years (p < 0.001), histologic grade 1 (p < 0.001), and pathologic stage I (p < 0.001) were associated with longer RFS but not with follow- up status. Multivariate analysis for overall survival (OS) revealed that patients in group I showed significantly improved OS (hazard ratio, 0.29; 95% CI, 0.23 to 0.37; p < 0.001). Additionally, age over 40 years, histologic grade I, and pathologic stage I were independent prognostic factors for OS. Conclusion Regular follow-up for patients with breast cancer after primary surgery resulted in clinically significant improvements in patient OS.

Citations

Citations to this article as recorded by  
  • Follow-up strategy and survival for five common cancers: A meta-analysis
    Boris Galjart, Diederik J. Höppener, Joachim G.J.V. Aerts, Christiaan H. Bangma, Cornelis Verhoef, Dirk J. Grünhagen
    European Journal of Cancer.2022; 174: 185.     CrossRef
  • Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
    Ji-Yeon Kim, Danbee Kang, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Han Yu, Se Kyung Lee, Young-Hyuck Im, Jin Seok Ahn, Eliseo Guallar, Juhee Cho, Yeon Hee Park
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
    Angela Lamarca, Hamish Clouston, Jorge Barriuso, Mairéad G McNamara, Melissa Frizziero, Was Mansoor, Richard A Hubner, Prakash Manoharan, Sarah O’Dwyer, Juan W Valle
    Journal of Clinical Medicine.2019; 8(10): 1630.     CrossRef
  • Analysis of patient-detected breast cancer recurrence
    Trishul Kapoor, Sean Wrenn, Peter Callas, Ted A. James
    Breast Disease.2017; 37(2): 77.     CrossRef
  • 11,867 View
  • 89 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Jae Myoung Noh, Yong Chan Ahn, Hyebin Lee, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Hyojung Park, Eonju Lee, Keunchil Park, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat. 2015;47(4):645-652.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.144
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the treatment outcomes following definitive bimodality concurrent chemoradiotherapy (CCRT) in patients with inoperable N2-positive stage IIIA (N2- IIIA) non-small cell lung cancer (NSCLC). Materials and Methods From May 1997 to December 2012, 65 out of 633 patients with N2-IIIA NSCLC received bimodality therapy. The treatment modality was selected during/after neoadjuvant CCRT in 21 patients or primarily at diagnosis in 44 through a multidisciplinary consensus meeting. The median age was 65 years (range, 36 to 76 years). Sixty patients (92.3%) had clinically evident N2 disease, while 22 (33.8%) had multi-station N2 involvement. The median radiation therapy dose was 66 Gy in 33 fractions, while the dose was elevated to 72 Gy in 13 patients who had a treatment break due to delayed decision regarding resectability. The most frequent chemotherapy regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin (54, 83.1%).
Results
During the median follow-up of 18.8 months (range, 1.6 to 173.1 months), 34 patients (52.3%) experienced disease progression, with distant metastasis being the most common first treatment failure pattern (23, 34.8%). The median and 2-year rates of progression-free survival were 18.8 months and 45.9%, respectively. The median and 2-year rates of overall survival were 28.6 months and 50.1%, respectively. Conclusion Definitive bimodality therapy in patients with N2-IIIA NSCLC demonstrated favorable outcomes, while trimodality therapy could be considered for candidates for less than pneumonectomy.

Citations

Citations to this article as recorded by  
  • Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
    Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
    Life.2022; 12(2): 292.     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
    Choi Eunsook, Park Sunhee
    Clinical Journal of Nursing Care and Practice.2021; 5(1): 015.     CrossRef
  • Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer
    Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung, Mei-Fang Wang
    Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1441.     CrossRef
  • Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
    The Oncologist.2019; 24(2): 157.     CrossRef
  • Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
    Junghee Lee, Hong Kwan Kim, Byung Jo Park, Jong Ho Cho, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Hongryull Pyo, Yong Chan Ahn, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jhingook Kim
    Lung Cancer.2018; 115: 89.     CrossRef
  • 13,546 View
  • 89 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
Lee Chun Park, Ji Yun Jeong, Jun Ho Ji, Silvia Park, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2014;46(2):200-203.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.200
AbstractAbstract PDFPubReaderePub

Cases of phenotypic heterogeneity of cells within tumors have recently been reported. Here, we report on a patient with characteristic intra-tumor double primary metastases in the lung. This patient was a 40-year-old Korean woman who had been diagnosed with breast cancer (T1N0M0, estrogen receptor/progesterone receptor/HER2 +/+/+) and papillary thyroid cancer three years prior and underwent a complete surgical resection followed by appropriate adjuvant treatment with radiation, hormone, and radioactive iodine. She was recently admitted for newly developed pulmonary nodules. Metastasectomy through video-assisted thoracoscopic surgery revealed recurrent double primary cancer with two different components (metastatic ductal carcinomas from the breast and metastatic papillary carcinomas from the thyroid gland) in each pulmonary nodule in the right upper lobe and right middle lobe. To the best of our knowledge, this is the first report of simultaneous recurrent double metastasis in one organ from different primary origins.

  • 11,744 View
  • 73 Download
  • 1 Web of Science
Close layer
A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians
Do Yeun Kim, Jin Seok Ahn, Kyung Hee Lee, Young Chul Kim, Juneyoung Lee, Si-Young Kim
Cancer Res Treat. 2014;46(2):131-140.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.131
AbstractAbstract PDFPubReaderePub
Purpose

Although cancer pain is prevalent, under-treatment still remains a problem. Knowledge of and compliance with guidelines for management of cancer pain were analyzed for exploration of physician-related barriers to cancer pain management. In addition, physicians' knowledge and its correlation with cancer pain control were audited.

Materials and Methods

From July 8 to December 2, 2010, a nationwide survey of house staff enquired about their knowledge of cancer pain control guidelines, and the medical records of patients under their care were analyzed.

Results

In total, 180 physicians participated in the study. Their average score for knowledge was 14.6 (range, 7 to 19; maximum possible, 20). When the knowledge score was divided into low, medium, and high scores, patients receiving care from physicians with high levels of knowledge tended to have better cancer pain control (p<0.001). Of the total patients with severe pain, 19.5% were not prescribed strong opioids, and 40% were not prescribed any medication for breakthrough pain.

Conclusion

Physicians' knowledge of guidelines for control of cancer pain showed an association with improvement of pain management. Overall adherence to the guidelines was lacking. Continuous interventions such as education and audits regarding cancer pain control guidelines for physician are needed.

Citations

Citations to this article as recorded by  
  • Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study
    Paolo Bossi, Tatiana Pietrzyńska, César Margarit Ferri, Irene Mansilla, Valeria Tellone, Sara Fioravanti, Giorgio Di Loreto, Alessandro Comandini
    Frontiers in Pain Research.2024;[Epub]     CrossRef
  • A Survey of Knowledge and Barriers of Healthcare Professionals toward Opioid Analgesics in Cancer Pain Management
    Nehad M. Ayoub, Malak Jibreel, Khawla Nuseir, Ghaith M. Al-Taani, Manish Gupta
    International Journal of Clinical Practice.2022; 2022: 1.     CrossRef
  • Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
    Paolo Bossi, Yolanda Escobar, Federico Pea
    Frontiers in Pain Research.2022;[Epub]     CrossRef
  • Ozono y COVID-19: bases fisiológicas y sus posibilidades terapéuticas según el estadio evolutivo de la infección por SARS-Cov-2.
    Marcos Edgar Fernández Cuadros, María Jesús Albaladejo Florin, Sandra Alava Rabasa, Daiana Peña Lora, Olga Susana Pérez Moro
    Revista de la Sociedad Española del Dolor.2021;[Epub]     CrossRef
  • Comparing Methadone Rotation to Consensus Opinion
    Michael A. Smith, Kyle C. Quirk, D'Anna C. Saul, Phillip E. Rodgers, Maria J. Silveira
    Journal of Pain and Symptom Management.2020; 59(1): 116.     CrossRef
  • Physician’s Attitude toward Treating Breakthrough Cancer Pain in Korea
    Min Seok Seo, Jae Yong Shim, Youn Seon Choi, Do Yeun Kim, In Gyu Hwang, Sun Kyung Baek, Jin Young Shin, Juneyoung Lee, Chang Geol Lee
    The Korean Journal of Hospice and Palliative Care.2017; 20(1): 18.     CrossRef
  • Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”
    Kieran Walsh
    Cancer Research and Treatment.2014; 46(4): 425.     CrossRef
  • 12,626 View
  • 105 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma
Ji Yun Lee, Sung Hee Lim, Ji Young Lee, Ji Hoon Kim, Ki Hong Choi, Keunchil Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat. 2013;45(4):343-348.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.343
AbstractAbstract PDFPubReaderePub
Tumor lysis syndrome (TLS) has rarely been observed in solid tumors. We report on a case of a patient with advanced invasive thymoma who developed tumor lysis syndrome after chemotherapy. The potential complications of TLS should be considered in treatment of extensive thymoma.

Citations

Citations to this article as recorded by  
  • Spontaneous tumour lysis syndrome as a rare presentation of thymoma with peripheral blood lymphocytosis
    Larry E Nyanti, Andy Sing Ong Tang, Adam Malik b Ismail, Lee Ping Chew, Tze Shin Leong
    Proceedings of Singapore Healthcare.2022;[Epub]     CrossRef
  • Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases
    Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi
    Cureus.2022;[Epub]     CrossRef
  • Spontaneous tumour lysis syndrome in cervical cancer
    Yu Kyung Kim, Ji Yeon Ham, Won-Kil Lee, Kyung Eun Song
    Journal of Obstetrics and Gynaecology.2017; 37(5): 679.     CrossRef
  • Ifosfamide/mesna/paclitaxel

    Reactions Weekly.2015; 1547(1): 151.     CrossRef
  • Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature
    Aibek E. Mirrakhimov, Alaa M. Ali, Maliha Khan, Aram Barbaryan
    Rare Tumors.2014; 6(2): 68.     CrossRef
  • 10,832 View
  • 58 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Cancer Res Treat. 2011;43(2):89-95.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.89
AbstractAbstract PDFPubReaderePub
PURPOSE
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.
MATERIALS AND METHODS
Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
RESULTS
The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).
CONCLUSION
Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'

Citations

Citations to this article as recorded by  
  • Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
    Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad
    Biomedicines.2024; 12(5): 1075.     CrossRef
  • Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways
    Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
    Phytotherapy Research.2024; 38(6): 2860.     CrossRef
  • Acro metastasis: A rare presentation in a common cancer
    Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour
    Current Problems in Cancer: Case Reports.2024; 14: 100292.     CrossRef
  • Concise review: breast cancer stems cells and their role in metastases
    Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard
    Annals of Medicine & Surgery.2024; 86(9): 5266.     CrossRef
  • Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
    Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras
    Current Oncology.2023; 30(2): 1416.     CrossRef
  • Surgery in the Setting of Metastatic Breast Cancer
    Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup
    Current Breast Cancer Reports.2023; 15(1): 37.     CrossRef
  • Team Approach: Management of Pathologic Fractures
    Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach
    JBJS Reviews.2023;[Epub]     CrossRef
  • Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
    Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477.     CrossRef
  • Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
    Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk
    BMC Cancer.2023;[Epub]     CrossRef
  • SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
    Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu
    Cell Research.2023; 33(6): 464.     CrossRef
  • Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
    Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill
    International Journal of Molecular Sciences.2023; 24(10): 8488.     CrossRef
  • Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
    Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun
    BMC Cancer.2023;[Epub]     CrossRef
  • Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
    Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo
    Journal of Clinical Medicine.2022; 11(13): 3589.     CrossRef
  • Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
    Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis
    Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong
    International Journal of Pharmaceutics.2022; 625: 122092.     CrossRef
  • Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
    Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq
    Cancer Management and Research.2022; Volume 14: 2519.     CrossRef
  • Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
    Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng
    Cancers.2022; 14(23): 5727.     CrossRef
  • Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
    E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse
    Critical Reviews in Oncology/Hematology.2021; 157: 103146.     CrossRef
  • Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
    Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
    European Journal of Cancer.2021; 144: 341.     CrossRef
  • Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone
    Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang
    Translational Oncology.2021; 14(2): 100993.     CrossRef
  • Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis
    Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim
    Bone.2021; 144: 115775.     CrossRef
  • Diagnosis and referral of adults with suspected bony metastases
    Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson
    BMJ.2021; : n98.     CrossRef
  • Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
    Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos
    Cancers.2021; 13(6): 1458.     CrossRef
  • Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
    Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue
    European Journal of Radiology.2021; 141: 109821.     CrossRef
  • Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
    Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser
    The Breast.2021; 58: 173.     CrossRef
  • Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
    Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
    Nature Communications.2021;[Epub]     CrossRef
  • Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
    Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak
    Clinical Breast Cancer.2020; 20(1): e54.     CrossRef
  • Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice
    Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas
    Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113.     CrossRef
  • MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9
    Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu
    Bone.2020; 130: 115139.     CrossRef
  • Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
    Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke
    Clinical Breast Cancer.2020; 20(3): 209.     CrossRef
  • Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
    Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti
    PLOS ONE.2020; 15(4): e0227256.     CrossRef
  • International Framework for Red Flags for Potential Serious Spinal Pathologies
    Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe
    Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350.     CrossRef
  • Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
    Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu
    The Oncologist.2020; 25(8): e1170.     CrossRef
  • Imaging diagnosis of metastatic breast cancer
    Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh
    Insights into Imaging.2020;[Epub]     CrossRef
  • Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells
    Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
    Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo
    Breast Cancer Research and Treatment.2020; 184(1): 23.     CrossRef
  • Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons
    Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli
    Frontiers in Bioengineering and Biotechnology.2020;[Epub]     CrossRef
  • The influence of breast cancer subtype on survival after palliative radiation for osseous metastases
    Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins
    Cancer Medicine.2020; 9(23): 8979.     CrossRef
  • Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
    Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao
    Breast Cancer Research and Treatment.2019; 173(1): 225.     CrossRef
  • Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
    Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li
    European Journal of Surgical Oncology.2019; 45(8): 1364.     CrossRef
  • The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis
    Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage
    Nature Communications.2019;[Epub]     CrossRef
  • Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
    Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova
    Clinical Breast Cancer.2018; 18(1): e41.     CrossRef
  • Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
    Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan
    Breast Cancer Research and Treatment.2018; 167(2): 579.     CrossRef
  • Breast cancer bone metastases: pathogenesis and therapeutic targets
    Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan
    The International Journal of Biochemistry & Cell Biology.2018; 96: 63.     CrossRef
  • Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data
    Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu
    Journal of Bone Oncology.2018; 11: 38.     CrossRef
  • Breast osteoblast-like cells: a new biomarker for the management of breast cancer
    Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno
    British Journal of Cancer.2018; 119(9): 1129.     CrossRef
  • Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
    Breast Cancer.2017; 24(3): 473.     CrossRef
  • Pattern of metastatic spread and subcategories of breast cancer
    Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner
    Archives of Gynecology and Obstetrics.2017; 295(1): 211.     CrossRef
  • Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
    Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini
    The Breast Journal.2017; 23(5): 610.     CrossRef
  • The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
    Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu
    The Journal of Pathology.2017; 242(1): 73.     CrossRef
  • Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
    I Bado, Z Gugala, S A W Fuqua, X H-F Zhang
    Oncogene.2017; 36(32): 4527.     CrossRef
  • Which red flags aid the early detection of metastatic bone disease in back pain?
    Laura Finucane, Susan Greenhalgh, James Selfe
    Physiotherapy Practice and Research.2017; 38(2): 73.     CrossRef
  • Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
    Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An
    Medicine.2017; 96(50): e8985.     CrossRef
  • Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
    Shinji Ohno
    Clinical Breast Cancer.2016; 16(4): 238.     CrossRef
  • Quality of life and symptom burden in patients with metastatic breast cancer
    Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma
    Supportive Care in Cancer.2016; 24(9): 4035.     CrossRef
  • Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
    Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann
    BMC Cancer.2016;[Epub]     CrossRef
  • Prolactin receptor in breast cancer: marker for metastatic risk
    Carrie S Shemanko
    Journal of Molecular Endocrinology.2016; 57(4): R153.     CrossRef
  • Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers
    Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno
    Clinical Breast Cancer.2015; 15(1): 37.     CrossRef
  • Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
    Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney
    Clinical Breast Cancer.2015; 15(2): 117.     CrossRef
  • Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
    D.K. Woolf, A.R. Padhani, A. Makris
    Annals of Oncology.2015; 26(6): 1048.     CrossRef
  • Survival time according to the year of recurrence and subtype in recurrent breast cancer
    Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura
    The Breast.2015; 24(5): 588.     CrossRef
  • Cases of Bone-only Metastasis in Recurrent Breast Cancer
    Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484.     CrossRef
  • Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
    June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh
    Journal of Breast Cancer.2013; 16(1): 66.     CrossRef
  • Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
    I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons
    Journal of Bone Oncology.2013; 2(4): 137.     CrossRef
  • Zooming in on the schedule of bone-modifying drugs
    Miguel Martin, Sara López-Tarruella
    The Lancet Oncology.2013; 14(7): 575.     CrossRef
  • Bone metastases: assessment, management and treatment options
    Carole Farrell
    British Journal of Nursing.2013; 22(Sup7): S4.     CrossRef
  • Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien
    K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah
    Médecine Nucléaire.2012; 36(10): 574.     CrossRef
  • 14,477 View
  • 141 Download
  • 67 Crossref
Close layer
Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
Cancer Res Treat. 2009;41(2):80-86.   Published online June 30, 2009
DOI: https://doi.org/10.4143/crt.2009.41.2.80
AbstractAbstract PDFPubReaderePub
Purpose

A novel chemically modified heparin derivative, heparin-deoxycholic acid nano-particles, has lower anticoagulant activity, and was recently reported to have significant anti-tumor effects on squamous head and neck cancer cells. Therefore, the aim of this study was to evaluate the anti-tumor effects of heparin-deoxycholic acid nano-particles in a human lung adenocarcinoma cell line.

Materials and Methods

An orthotopic lung cancer model in 16 mice was developed using intra-thoracic injections of 0.5×106 PC14PE6 cells. Ten days after inoculation, the mice were divided into two groups. PBS and Heparin-DOCA particles were injected once a day every 3 days in the tail vein, for a total of 5 injections. The body weight and survival of each mouse were monitored and the tumor size in the lung was measured by SPECT-CT before and after heparin-DOCA nano-particle treatment.

Results

IThe HD particles had no significant cytotoxicity when the PC9 cells were treated in vitro. There was no statistical difference in tumor size, body weight and survival between the HD treated and control groups in vivo. Furthermore, there was no difference in the amount of CD31 between tumor tissues in the two study groups.

Conclusion

HD synthesized with unfractionated heparin had no apparent inhibitory effects on tumor growth in a PC14PE6 cell induced orthotopic lung cancer mouse model. The HD particles did not significantly inhibit tumor-induced angiogenesis at the tumor sites.

Citations

Citations to this article as recorded by  
  • Improvement of orthotopic lung cancer mouse model via thoracotomy and orotracheal intubation enabling in vivo imaging studies
    Geun Ho Im, Moon-Sun Jang, Julius Juhyun Chung, Kyoung-Nam Kim, Jae-Hun Kim, Sun I Kim, Jung Hee Lee
    Laboratory Animals.2014; 48(2): 124.     CrossRef
  • The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil
    Clare A. Watson, Kara L. Vine, Julie M. Locke, Anna Bezos, Christopher R. Parish, Marie Ranson
    Anti-Cancer Drugs.2013; 24(7): 704.     CrossRef
  • 9,516 View
  • 47 Download
  • 2 Crossref
Close layer
Mouse Orthotopic Lung Cancer Model Induced by PC14PE6
Zheng Yun Cui, Jin Seok Ahn, Jee Yun Lee, Won Seog Kim, Ho Yeong Lim, Hyun Jung Jeon, Soo Won Suh, Jin Hoon Kim, Won Ho Kong, Ji Min Kang, Do Hyun Nam, Keunchil Park
Cancer Res Treat. 2006;38(4):234-239.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.234
AbstractAbstract PDFPubReaderePub
Purpose

This study was undertaken to investigate in detail the xenograft mouse orthotopic lung cancer model induced by PC14PE6 adenocarcinoma cells.

Materials and Methods

Three cell doses (0.5×106; 1×106; 2×106) of PC14PE6 cells were injected into the lungs of male BALB/c nude mice by the intrathoracic injection method. The lung and other organs, including brain, liver, spleen, kidney, muscle, adrenal gland, and lymph node on knee, were removed and stained with H/E to detect the presence of tumor cells.

Results

The reliable tumorigenicity time in the PC14PE6 adenocarcinoma cell-inoculated BALB/c nude mouse was 10 days after intrathoracic injection. The average life span of the three groups after inoculation was 14 days in the 2×106 cells inoculum group; 25 days in the 1×106 cells inoculum group; and 32 days in the 0.5×106 cells inoculum group. The PC14PE6 adenocarcinoma cells induced orthotopic lung cancer limited within the thorax.

Conclusions

This orthotopic lung cancer model is an efficient cancer model with easy inoculation methods, rapid and high tumorigenicity, and simple monitoring methods for metastasis.

Citations

Citations to this article as recorded by  
  • Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor
    Natalia Khromova, Maria Vasileva, Vera Dugina, Dmitry Kudlay, Peter Chumakov, Sergei Boichuk, Pavel Kopnin
    Cancers.2024; 16(6): 1123.     CrossRef
  • Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand
    M. Isabel Acuña, Ana R. Rubio, Marta Martínez-Alonso, Natalia Busto, Ana María Rodríguez, Nerea Davila-Ferreira, Carl Smythe, Gustavo Espino, Begoña García, Fernando Domínguez
    Cancers.2022; 15(1): 107.     CrossRef
  • Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
    Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux, Rémy Pedeux
    BMC Cancer.2021;[Epub]     CrossRef
  • Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach
    Hor-Yue Tan, Venice Wing-Tung Ho, Yau-Tuen Chan, Cheng Zhang, Ning Wang, Wen Xia, Yibin Feng
    Pharmacological Research.2020; 155: 104415.     CrossRef
  • Metastatic Spread from Abdominal Tumor Cells to Parathymic Lymph Nodes
    Gábor Király, Zoltán Hargitai, Ilona Kovács, Gábor Szemán-Nagy, István Juhász, Gáspár Bánfalvi
    Pathology & Oncology Research.2019; 25(2): 625.     CrossRef
  • LPP inhibits collective cell migration during lung cancer dissemination
    S Kuriyama, M Yoshida, S Yano, N Aiba, T Kohno, Y Minamiya, A Goto, M Tanaka
    Oncogene.2016; 35(8): 952.     CrossRef
  • Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer
    Erea Borrajo, Raquel Abellan-Pose, Atenea Soto, Marcos Garcia-Fuentes, Noemi Csaba, Maria J. Alonso, Anxo Vidal
    Journal of Controlled Release.2016; 238: 263.     CrossRef
  • Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpression
    Hideaki Ogiwara, Mariko Sasaki, Takafumi Mitachi, Takahiro Oike, Saito Higuchi, Yuichi Tominaga, Takashi Kohno
    Cancer Discovery.2016; 6(4): 430.     CrossRef
  • Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice
    T. Jaroensong, Y. Endo, S.‐J. Lee, A. Kamida, M. Mochizuki, R. Nishimura, N. Sasaki, T. Nakagawa
    Veterinary and Comparative Oncology.2012; 10(4): 274.     CrossRef
  • A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer
    Bo Li, Artour Torossian, Wenyan Li, Stephen Schleicher, Kathy Niu, Nicholas J. Giacalone, Sung June Kim, Heidi Chen, Adriana Gonzalez, Luigi Moretti, Bo Lu
    Radiation Research.2011; 176(4): 486.     CrossRef
  • Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy
    Ewa D. Micewicz, Chun-Ling Jung, Dorthe Schaue, Hai Luong, William H. McBride, Piotr Ruchala
    International Journal of Peptide Research and Therapeutics.2011; 17(3): 247.     CrossRef
  • The Incidence Rate and Severity of Orthotopic Lung Cancer in an Animal Model Depends on the Number of A549 Cells and Transplantation Period
    Jinsoo Lee, Young-Ah Han, Hyo-Seon Yang, Jeong-Ah Song, Young-Su Yang, Soonjin Kwon, Min-Sung Kang, Kyuhong Lee, Jeong-Doo Heo, Kyu-Hyuk Cho, Chang Woo Song
    Laboratory Animal Research.2010; 26(4): 369.     CrossRef
  • Tumorigenesis after Injection of Lung Cancer Cell Line (SW-900 G IV) into the Pleural Cavity of Nude Mice
    Eok-Sung Park, Song-Myung Kim, Jong-In Kim
    The Korean Journal of Thoracic and Cardiovascular Surgery.2010; 43(6): 588.     CrossRef
  • Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
    Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
    Cancer Research and Treatment.2009; 41(2): 80.     CrossRef
  • 16,031 View
  • 126 Download
  • 14 Crossref
Close layer
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer
Jung Ae Lee, Keun Seok Lee, Jin Seok Ahn, Jae Ho Byun, Hun Ho Song, Dae Young Zang, Young Iee Park, Young Suk Park, Eun Kyung Mo, Dong Kyu Kim, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Soo Mee Bang, Gye Young Park, Jeong Woong Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2003;35(3):239-244.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.239
AbstractAbstract PDF
PURPOSE
Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS: Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS: The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed.
CONCLUSION
The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.

Citations

Citations to this article as recorded by  
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 4,757 View
  • 32 Download
  • 1 Crossref
Close layer
A Small Cell Lung Cancer Concurrently Diagnosed with Paraneoplastic Dermatomyositis
Hyung Seok Lee, Dae Young Zang, Young Il Seo, Dong Gyu Kim, Eun Jung Kim, Jin Seok Ahn, Hye Rim Park
Cancer Res Treat. 2003;35(2):161-164.   Published online April 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.2.161
AbstractAbstract PDF
Dermatomyositis is an inflammatory myopathy, of unknown etiology, which is characterized by cutaneous rashes, accompanied by progressive and symmetric proximal muscle weakness. Especially in older people, the incidences of malignant conditions appear to be increased in dermatomyositis patients, and the prognosis is very poor. Because dermatomyositis may occur as a paraneoplastic syndrome, extensive screening tests, for an occult malignant neoplasm, should be conducted in older dermatomyositis patients. We experienced a case of small cell lung cancer, which had a very rapid and catastrophic clinical course, in a 63-year-old male patient with dermatomyositis. We report this case, and review the literature on the relationship of dermatomyositis and malignancy.

Citations

Citations to this article as recorded by  
  • Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report
    Andrew J. Beel, David S. Demos, Alfred Chung, Charles Liao, Natalie S. Lui
    Journal of Cardiothoracic Surgery.2018;[Epub]     CrossRef
  • A case report of dermatomyositis associated with small cell lung cancer
    Wha-Yong Lee, Jack Kastelik, Anne Campbell, Ged Avery, Damian McGivern, Mike Lind
    Tumori Journal.2012; 98(6): e158.     CrossRef
  • 4,136 View
  • 37 Download
  • 2 Crossref
Close layer
A Phase II Study of Ifosfamide, Carboplatin, and Epirubicin (ICE) Combination Chemotherapy for Extensive Disease of Small Cell Lung Cancer
Jae Ho Byun, In Sook Woo, Hun Ho Song, Keun Seok Lee, Jin Seok Ahn, Dae Young Jang, Jung Ae Lee, Young Lee Park, Young Suk Park
Cancer Res Treat. 2002;34(6):416-420.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.416
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and safety of ifosfamide, carboplatin and epirubicin (ICE) combination chemotherapy for extensive disease small cell lung cancer (SCLC) patients, who had received no previous chemotherapy, we performed phase II trial between August 1998 and January 2001.
MATERIALS AND METHODS
The study group comprised of 21 patients. Ifosfamide, 1,500 mg/m2, was given with mesna, 900 mg/m2, intravenously for 12 hours on days 1, 2 and 3, and carboplatin, 4.5 mg/ml/min, for target AUC, and epirubicin, 60 mg/m2, were given intravenously for 90 minutes on day 1. The cycle of treatment was repeated at 4 week intervals.
RESULTS
Twenty-one patients with extensive disease SCLC were treated at Hallym University between August 1998 and January 2001. One patient was unable to be evaluated because of lost to follow-up. Of the 20 patients able to be evaluated, an objective response was observed in 13 (65%). There were no complete responses. The median response duration, time to progression and median overall survival were 15.4, 18.3 and 34 weeks, respectively. Toxicities were acceptable, with dose reduction for myelosuppression necessary in only a minority of the patients. A total of 85 cycles of chemotherapy were given to the patients. The median number of cycles completed was 4. Grade III and IV hematological toxicities included anemia (4.7%), neutropenia (3.5%) and thrombocytopenia (3.5%). Most non-hematological toxicities were grade I or II.
CONCLUSION
These results suggested that ICE combination chemotherapy for extensive disease SCLC is effective, and can be safely administered with acceptable toxicities.
  • 4,187 View
  • 24 Download
Close layer
Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5-Fluorouracil-Pretreated Patients with Metastatic Colorectal Cancer
Soo Mee Bang, Eun Kyung Cho, Jae Hwan Oh, Heung Moon Chang, Jin Seok Ahn, Jung Ae Lee, Young Iee Park, Myung Jue Ahn, Young Suk Park, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2001;33(5):414-419.   Published online October 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.5.414
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer who previously treated with 5-FU-based chemotherapy.
MATERIALS AND METHODS
Between April 1999 and January 2001, thirty-two patients were enrolled in this study. Oxaliplatin 130 mg/m2 was given intravenously (IV) on day 1 as was 5-FU 500 mg/m2 IV followed by continuous infusion of 5-FU 3,000 mg/m2 and LV 100 mg/m2 for 48 hours administered every 3 weeks. Six patients had received 5-FU as an adjuvant setting and 26 patients as a palliative regimen.
RESULTS
The median age of the patients was 50 years (range; 19-69) and the dominant sites of metastasis were the liver, lung or both in 9, 5 and 2 patients respectively. In 30 evaluable patients, the overall response rate was 27% including 1 complete response and 7 partial responses. The median response duration was 28 weeks (95% confidence interval; 22~34 weeks) and the median progression free survival of all patients was 24 weeks (95% confidence interval; 15~33 weeks). A median 5 cycles (range; 2~9) and total 155 cycles were performed in 32 patients. 150 cycles were evaluable for toxicity. The most common hematologic toxicity was grade 1~2 anemia in 78 cycles (52%). Leukopenia (39%) and thrombocytopenia (23%) were fully reversible. The most common non-hematologic toxicity was nausea/vomiting (43/30%) followed by diarrhea (23%), hepatotoxicity (21%) and neurotoxicity (21%). One patient ceased therapy due to grade 4 diarrhea. No other severe toxicity interrupted this treatment.
CONCLUSION
Oxaliplatin, 5-FU and LV in combination showed significant activity in previously treated metastatic colorectal cancer with favorable toxicity.

Citations

Citations to this article as recorded by  
  • Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer
    Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim
    Cancer Research and Treatment.2005; 37(4): 212.     CrossRef
  • 5,352 View
  • 27 Download
  • 1 Crossref
Close layer
Efficacy of Combination Chemotherapy with Vinorelbine, Ifosfamide, and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
Heung Moon Chang, Jung Ae Lee, Jin Seok Ahn, In Sook Woo, Young Iee Park, Jee Woong Son, Seung Joon Lee, Dong Kyu Kim, Eun Kyung Mo, Myung Jae Park, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Young Suk Park
J Korean Cancer Assoc. 2000;32(3):612-618.
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine, ifosfamide, and cisplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Patients with unresectable, pathologically proven non-small cell lung cancer who had no prior chemotherapy were eligible. Patients received vinorelbine (25 mg/m2, iv., D1 & 8), ifosfamide (1.5 g/m2, iv., D1-3 with mesna), and cisplatin (60 mg/m2, iv., D1). The treatment was repeated every 3 weeks.
RESULTS
Between degrees Ctober, 1997 and June, 1999, 26 patients were enrolled. Median age was 61. 1 patient had stage IIIA, 13 had stage IIIB, and 12 had stage IV. Patients with adendegrees Carcinoma were 15, squamous cell carcinoma were 11. Of 22 evaluable patients, objective responses were observed in 9 patients (response rate: 40.9%, CR: 1 (4.5%), PR 8 (36.4%)). Median duration of response was 48 weeks. Median overall survival was 52 weeks. Grade 3-4 leukopenia was observed in 10.2% of the 88 courses. There was 1 death related to febrile neutropenia. Non- hematologic toxicities were mild.
CONCLUSION
We concluded that combination chemotherapy with vinorelbine, ifosfamide, and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer, and phase III randomized trial is needed to compare this regimen to other cisplatin-based regimens.
  • 2,988 View
  • 32 Download
Close layer
COPP/ABV Hybrid Chemotherapy in Pateints with Hodgkin's Disease
Jin Seok Ahn, Keun Seok Lee, Jong Tae Lee, Seok Ah Lim, Dae Seok Heo, Young Joo Bang, Sun Yang Park, Byung Kook Kim, No Kyung Kim
J Korean Cancer Assoc. 1998;30(4):818-826.
AbstractAbstract PDF
PURPOSE
MOPP/ABV hybrid regimen incorporates MOPP and ABVD into a single regimen on the tenets of the Goldie-Coldman hypothesis. This study was performed to determine the efficacy of COPP/ABV hybrid regimen, in which cyclophosphamide was substituted for mechlorethamine, in patients with advanced Hodgkin's disease.
MATERIALS AND METHODS
Patients with advanced Hodgkin's disease were treated with cyclophosphamide(600 mg/m2 iv, Dl), vincristine(1.4 mg/m2 iv, D1), procarbazine(100 mg/m2/d po, D1-7), prednisolone(40 mg/m2/d po D1-14), doxorubicin(35 mg/m2 iv, D8), bleomycin(10 mg/m2 iv, D8) and vinblastine(6 mg/m2 iv, D8). The treatment was repeated every 4 weeks.
RESULTS
Between Aug. 1989 and Aug. 1996, 28 patients were enrolled. The median age was 33 years. Twenty one(75%) were previously untreated, newly diagnosed patients and 7(25%) were those who had relapsed after previous radiotherapy(RT). The common histologic types were nodular sclerosis(46%) and mixed cellularity(36%). Twenty three (82%) patients achieved complete remission(CR), three(11%) with the assistance of involved-field RT. Only one patient was primary treatment failure. The median follow-up duration was 56 months. Of the 23 patients achieving CR, three(13%) relapsed. Five-year relapse-free survival was 84.4%. Eight patients died. Five-year overall survival rate was 66.6% and 5-year failure-free survival rate was 66.3%. The survival rate of those who had relapsed after previous RT was significantly lower than that of newly diagnosed patients(P=0.03). The hematologic toxicities were common, but nonhernatologic toxicities were uncommon. Five patients died of treatment-related pneumonia or sepsis. Among them, four were those who had relapsed after previous RT.
CONCLUSION
COPP/ABV hybrid regimen could cure significant proportion of patients with advanced Hodgkin's disease but the treatment-related mortality was high, especially in those who had relapsed after previous RT. Another regimen should be considered for those who received previous RT.
  • 5,189 View
  • 88 Download
Close layer
Chemopotentiation of Fresh Acute Myelogenous Leukemic Cells by Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor ( GM-CSF ) and Methotrexate
Heung Tae Kim, Jin Seok Ahn, Eun Shil Kim, Yung Jue Bang, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 1998;30(2):357-369.
AbstractAbstract PDF
No abstract available.
  • 2,117 View
  • 13 Download
Close layer
Phase 2 Trial of FLP ( 5-FU , Leucovorin , Cisplatin ) Combination Chemotherapy for Advanced Gastric Cancer
Young Iee Park, Moon Hee Lee, Sung Woo Han, Woo Jung Park, Dong Gyu Kim, Jin Lee, Jin Seok Ahn, Jung Ae Rhee, In Sook Woo, Young Suk Park
J Korean Cancer Assoc. 1998;30(1):55-62.
AbstractAbstract PDF
PURPOSE
Advanced gastric cancer, the most common malignancy in Korea is a kind of systemic disease. At dignosis, 50~80% of patients have systemic cancer. Therefore, the most patients require systemic chemotherapy. Cisplatin and 5-FU have been suggested to be active in the treatment of gastric cancer, a high response rate was observered with a combination of 5-FU infusion and cisplatin, and the biochemical modulation of 5-FU by leucovorin has been demonstrated to enhance the activity of 5-FU in gastrointestinal tract cancer.
MATERIALS AND METHODS
The patients with advanced gastric cancer whose disease had relapsed or unresectable were treated with 5-FU(800 mg/m2 12 hr IV infusion, D 1~5), leucovorin(20 mg/m2 IV, D 1~5, max. 30 mg), cisplatin(100 mg/m2 15min IV dripping, D1). The cycles of treatment were repeated at 3-weeks intervals.
RESULTS
Between Sep. 1994 and Aug. 1996, previously untreated 44 patients(39 eligible patients) were admitted to this study, the median age was 55 years(range 17~73) and male to female ratio was 20:19. The rate of complete remission was 5%(2/39), the rate of partial remission was 21%(8/39). The median-response duration was 26 weeks(5+~38+ ). The median-time to progression was 25 weeks(4+~62+). The range of overall survival time was from 4 to 62+ weeks. 24 weeks survival rate was 71.5% but the median survival time was not reached. The leukopenia and anemia were the main hematologic toxicities. Non-hematologic side effects were nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy. These toxicities were observed commnonly, but tolerable. Two treatment-related deaths were associated with sepsis.
CONCLUSION
Based on these results, FLP combination chemotherapy seems to be a moderate efficacy for advanced gastric cancer with tolerable toxicities. To confirm the efficacy further, the long-term follow up and a large scale of clinical studies are needed.
  • 2,869 View
  • 14 Download
Close layer
Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data
Kyu Yean Kim, Ho Cheol Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Chang Min Choi, Seung Hun Jang, Jeong Uk Lim, Korean Association for Lung Cancer, Korea Central Cancer Registry
Received January 19, 2024  Accepted July 8, 2024  Published online July 10, 2024  
DOI: https://doi.org/10.4143/crt.2024.073    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent development in perioperative treatment of resectable non–small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treatment in resectable NSCLC patients; however, studies are required to show which subgroup of patients are at a high risk of relapse and require adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment. This study evaluated risk factors for postoperative relapse among patients who underwent complete resection.
Materials and Methods
Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
Results
A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
Conclusion
Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.
  • 1,003 View
  • 69 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP